Archives: BioMedWire

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has inked a master supply agreement with two German diagnostics, testing, and medical logistics companies: Beovita GmbH & Co. KG and Tackleberries GmbH. The two companies run 10 COVID-19 test centers in Berlin. The supply agreement outlines the delivery of approximately 1,000 of XPhyto’s proprietary Covid-ID Lab tests to test centers in Berlin. Delivery is scheduled to begin this week, followed by a brief trial period to integrate and evaluate XPhyto’s new PCR test system with commercial operations expected to commence upon delivery of kits. According to the announcement, the samples processing for the lab will take place at the sample collection site, which is a significant change from conventional PCR testing models where samples are collected and then shipped for processing to centralized labs. It is anticipated that XPhyto’s PCR lab tests will yield faster results, more versatile test center options and cost effectiveness at lower testing volumes. “This is a major commercial milestone for XPhyto,” said XPhyto Therapeutics CEO and director Hugh Rogers in the press release. “The successful launch of our first diagnostic product, Covid-ID Lab, represents significant validation of our rapid point-of-care care diagnostic business strategy. Our portable Covid-ID Lab is designed to be one of the fastest PCR systems in the world, while our platform is economic at low to mid-range sample volumes. We anticipate strong and sustainable demand for our rapid and versatile PCR system and look forward to further expanding our reach.”

To view the full press release, visit https://ibn.fm/PhjLO

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany. The company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has reported its financial results for fiscal year ended March 31, 2021; the company also provided a corporate update, noting that its PALISADE-1 phase 3 trial designed to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (“SAD”) is under way. The announcement also noted that the company is preparing to initiate several exploratory phase 2A clinical trials of PH94B in additional anxiety disorders; progress in efforts to initiate a U.S. multicenter phase 2B clinical trial of PH10 as a potential rapid-onset, standalone treatment for major depressive disorder; and begin a phase 1B clinical trial of AV-101 with probenecid, which, if successful, has the potential to support exploratory phase 2A development of the combination in several CNS disorders. “Our fiscal year 2021 was transformative, involving several drug-development, financial and regulatory milestones that fortified the foundation for our very strong start this fiscal year,” said VistaGen CEO and director Shawn K. Singh in the press release. “Notably, we achieved an important consensus with the U.S. Food and Drug Administration regarding our PALISADE phase 3 program for PH94B in social anxiety disorder. Building on that positive meeting, we completed a PH94B collaboration in ex-U.S. markets, strengthened our balance sheet with substantial investment from numerous long-biased, healthcare-focused institutional investors, and advanced several development programs across our CNS pipeline, most notably preparations for PALISADE-1, our U.S. multicenter phase 3 clinical study of PH94B as a potential rapid-onset, acute treatment of anxiety in adults with social anxiety disorder. If successful, PALISADE-1 is designed to be among the studies necessary to support a potential PH94B New Drug Application to the U.S. Food and Drug Administration in 2023. We recently initiated PALISADE-1, moving us closer to our goal of going beyond the current treatment paradigm for social anxiety disorder, not only displacing antidepressants, benzodiazepines and beta blockers but also reaching those in need of support who find those therapies to be undesirable or inadequate. We anticipate topline data from PALISADE-1 in mid-2022. Later this year, we expect to launch PALISADE-2, a second U.S. multicenter phase 3 clinical study of PH94B designed to be substantially similar to PALISADE-1 and equally supportive of our U.S. New Drug Application goal.”

To view the full press release, visit https://ibn.fm/FqxeO

About VistaGen Therapeutics Inc.

VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information about the company, please visit www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

The majority of individuals who contract the coronavirus suffer from the symptoms of coughing, fever and difficulty breathing before recovering in about two weeks. However, some individuals suffer persistent symptoms, informally referred to as long COVID. Researchers estimate that these individuals make up 10% to 30% of the population.

While researchers have been unable to find a definitive cause as to why some people suffer from long-term symptoms, they have proposed a few theories as well as growing information about the disease…

Read more >>

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that the U.S. Food and Drug Administration granted Fast Track Designation for Berubicin, the company’s lead investigational drug. The status was received for the company’s evaluation of Berubicin for the treatment of patients with recurrent glioblastoma multiforme (“GBM”). An anthracycline, Berubicin falls in a class of anticancer agents that are among the most powerful chemotherapy drugs, proven to be effective against more types of cancer than any other category of chemotherapeutic agents. Fast Track Designation provides opportunities to expedite the development and review process for drugs intended to treat serious or life-threatening conditions when those drugs show potential to address unmet medical need. CNS has already begun patient enrollment in its upcoming study of Berubicin for the treatment of recurrent glioblastoma multiforme. “Receiving Fast Track Designation from the U.S. FDA is a huge achievement in our advancement of Berubicin for the treatment of glioblastoma, the most aggressive, deadly and treatment-resistant type of cancer that forms in the brain,” said CNS Pharmaceuticals CEO John Climaco in the press release. “If there were ever a disease where the unmet clinical need demands action, it is GBM. Patients have almost no meaningful options, and thousands lose their fight against this terrible cancer every year. With this designation, we now have an accelerated pathway to approval for Berubicin and a clear opportunity to more expediently bring this potentially impactful investigational therapy to individuals battling this challenging disease.”

To view the full press release, visit https://ibn.fm/h7cWG

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme, an aggressive and incurable form of brain cancer.

Additionally, CNS Pharmaceuticals is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain, pancreatic and ovarian cancers as well as lymphomas. For more information about the company, please visit www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, sublicenses the compound Berubicin to WPD Pharmaceuticals for 30 countries mainly in Europe and Asia. WPD, a clinical-stage pharmaceutical company, today provided an update on its Berubicin drug candidate clinical development program for the treatment of glioblastoma multiforme (“GBM”). According to the update, WPD plans to commence its Phase Ib/II Study of Berubicin in the treatment of glioblastoma in the second half of 2021. In addition, CNS Pharmaceuticals has announced open enrollment in the United States for its clinical study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM. “I am very pleased and excited about the development we have made on Berubicin both in the United States and in Europe. Our combined WPD and CNS clinical studies are going to start to recruit patients shortly, which is an exciting step in the development programs,” said Mariusz Olejniczak, CEO of WPD. “To ensure patients are informed and updated on possible sites, we will use clinicaltrials.gov as the primary source of information. We are hopeful that this is the first step in changing the landscape of glioma treatment with products in our pipeline and trough collaboration with different companies, scientific institutions and our license partners. I would like to take an opportunity to thank both the WPD and CNS teams and our vendors and partners including WWCT and IAG for the hard work during pandemic months.”

To view the full press release, visit https://ibn.fm/xzjYa

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. During 2021, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

InvestorBrandNetwork (“IBN”), an innovative corporate communications firm and content distributor, today announced that it is continuing its collaboration with Roth Capital Partners (“Roth”) for its Virtual Healthcare Private Company Forum. The event is shining the spotlight on a diverse selection of companies across biotechnology, pharmaceuticals and medical technologies verticals and featuring engaging discussion panels designed to offer novel insights into some of the latest developments within the healthcare space. The panels will cover a number of topics, including “Novel Approaches to Tumor Eradication,” “Natural Killer Cell Approaches to Eradicate Tumors,” and the “Next Wave of Psychedelic Drug Developers.” IBN, operating in the capacity of media sponsor, is furthering distribution of content generated for the event. “Our team is excited to be collaborating once again with the Roth Capital team for today’s Virtual Healthcare Private Company Forum,” said Jonathan Keim, communications director for IBN. “We are leveraging our communications solutions to heighten visibility of the event and also widen the reach to additional investor audiences who would be interested in learning more about the participating companies.”

To view the full press release, visit https://ibn.fm/MXTSQ

About InvestorBrandNetwork

The InvestorBrandNetwork consists of financial brands introduced to the investment public over the course of more than 15 years. IBN has amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand its branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve its increasingly diversified list of clients. For more information on IBN, visit www.investorbrandnetwork.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

A study recently published in the “Journal of Clinical Psychopharmacology” has found that some domestic mass shooters in the United States suffer from psychiatric disorders that they haven’t been treated for or received medication for. The report, written by Ira D. Glick and colleagues, highlighted that while most individuals who are mentally ill aren’t violent and most who are violent aren’t mentally ill, their research would be useful to lawyers, mental health providers and the public, who needed to be aware of the fact that some unmedicated individuals pose a higher risk of violence.

For their study, the researchers identified 115 individuals who had committed a mass shooting in the country between 1982 and 2019…

Read more >>

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

A recent report released by researchers from the University of Dundee has found that prescriptions given to alleviate pain after operations are a primary cause of the opioid crisis in some countries. The study, which was reported in “The Lancet,” was co-authored by Prof. Lesley Colvin from the institution. It compiled evidence describing the role surgeries play in the crisis.

The authors of the report deduce that pain management has been a significant contributor to the opioid crisis on account of improper prescriptions…

Read more >>

NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

• Dr. Dave Singh, Vivos Therapeutics Inc. founder and Chief Medical Officer, releases his new book titled Pneumopedics and Craniofacial Epigenetics
• The book is the product of Dr. Singh’s years of research and is a chronology of Vivo Therapeutics’ strides in innovation
• The book mainly covers craniofacial growth and developmental Genetics
• It also highlights the relationship between dentofacial anomalies and developmental deficiencies associated with downstream conditions such as Obstructive Sleep Apnea (“OSA”)

Since its inception, Vivos Therapeutics (NASDAQ: VVOS) has been a trailblazer in diagnosing and treating mild-to-moderate Obstructive Sleep Apnea (“OSA”). Its main product — Vivos System — results from years of research and has been instrumental in treating the condition among adults. Dr. G. Dave Singh, the personality behind Vivos Therapeutics, shares the process behind Vivos System’s innovation and the scientific and biological foundation of the product in his new book titled Pneumopedics and Craniofacial Epigenetics. He details his research’s progress and Vivo Therapeutics’ achievements over the years. Dr. Singh’s primary goal with this book is to spread the word far and wide about the technology, how it can help people think about health conditions such as OSA, and how such ailments are treated going forward. He covers craniofacial growth along with developmental Genetics. By doing so, he addresses the link between dentofacial anomalies and developmental deficiencies that are associated with… Read More>> NOTE TO INVESTORS: The latest news and updates relating to Vivos Therapeutics are available in the company’s newsroom at http://ibn.fm/VVOS About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that it will host a conference call to provide a business update and discuss financial and operating results for its fiscal year ended March 31, 2021. The call is scheduled to begin at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on Tuesday, June 29, 2021. VistaGen CEO Shawn Singh and other members of the company’s management team will host the call and provide an update on VistaGen’s recent developments, milestones during its 2021 fiscal year, as well as discuss certain target milestones and future goals. Interested parties may join by dialing 1-877-407-9716 (U.S./Toll-Free) or 1-201-493-6779 (International/Toll) and entering conference ID: 13720908. A live audio webcast of the conference call will also be available at https://ibn.fm/WtQNv.

To view the full press release, visit https://ibn.fm/FBpgq

About VistaGen Therapeutics Inc.

VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated profile and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• More than 3,200 pharmaceutical and biotech companies, plus government and academic organizations attended latest BIO Conference
• Predictive Oncology’s Helomics, TumorGenesis, Soluble Biotech all attended the virtual conference from June 14-18, 2021
• Companies leveraged different components of the conference to entertain new partnerships or customers

Every industry has a revolving calendar of events, but some are “must attends” due to their global reach and prospective deal flow, like conferences put on by Biotechnology Innovation Organization, or just “BIO” as it’s known. This year, three wholly owned subsidiaries of Predictive Oncology (NASDAQ: POAI) – Helomics, TumorGenesis and Soluble Biotech – attended BIO DIGITAL, a premier international biotech partnering event held virtually on June 10-11 & 14-18, 2021. The Predictive Oncology companies attended the event during the second leg of the conference. BIO is the world’s largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the U.S. and in 30+ countries. This year’s… Read More>> NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

• As a leading innovator in brain diagnostics technology, BRSF appears well placed to spot and predict driving forces behind the industry’s expected rapid growth
• BRSF’s Marketing Director was featured in an article giving prediction about key trends driving brain monitoring space in 2021
• BRSF poised to remain at EEG forefront as exciting new opportunities lay ahead for this growing sector

Recognized as a leading innovative player in the brain monitoring space, Brain Scientific (OTCQB: BRSF) continues to be at the forefront of what is next in neurology technology. The Company’s Marketing Director, Irina Nazarova, was featured in Tech Times, a publication reporting on the latest innovations and developments in technology, science, and health industries, where she outlined key brain monitoring trends to watch in 2021 (https://ibn.fm/txDqZ). Technology is advancing at an accelerated rate, pushing boundaries on what is possible and at what costs across neurology medical devices. As a result, brain monitoring is becoming as popular and widespread as… Read More>> NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Healthy Extracts (OTCQB: HYEX) develops, sells and distributes proprietary products with proven health benefits through its portfolio of wholly owned subsidiaries that currently comprises Ultimate Brain Nutrients(TM) (“UBN”) and BergametNA(TM). UBN creates formulations that improve brain health while BergametNA develops powerfully proven supplements sourced from the Citrus Bergamot Superfruit(TM) (“bergamot”) and which target cardiovascular and immune health. “Bergamot has a host of health benefits as it is a source of high concentrations of polyphenolic flavanones, measured in terms of the bergamot polyphenolic fraction (‘BPF’),” reads a recent article. Dr. Gerald Haase, MD, a clinical professor of surgery at the University of Colorado School of Medicine, observes that the higher the BPF, the greater the supplement’s effectiveness. “With BergametNA only using the bergamots with the highest BPF (47%), customers are guaranteed to extract more out of the powerfully proven plant-based supplements than from competitor’s products, which are sourced from bergamots whose BPF concentrations range between 30% and 37%.”

To view the full article, visit https://ibn.fm/oIMHx

About Healthy Extracts Inc.

“Live Life Young Again”

Healthy Extracts serves as a platform for developing and acquiring complementary companies that feature science-forward, clinically proven, plant-based and proprietary products in select high-margin and high-growth categories within the multibillion-dollar nutraceuticals market – the first two multimillion-dollar examples of which have already been launched.

Company subsidiaries BergaMet NA(TM) and Ultimate Brain Nutrients(TM) (“UBN”) are providers of nutraceutical natural heart and brain health supplements, including the only heart health supplement containing Citrus Bergamot SuperFruit(TM), the highest quality and concentration of polyphenols and flavonoids available anywhere in the world and exclusive to BergaMet NA in North America and backed by 17 clinical studies. UBN’s KETONOMICS(R) proprietary formulations improve brain health, including memory, cognition, focus and neuro-energy, and have multiple intellectual property license opportunities for monetizing the company’s portfolio. UBN has six unique formulation patents — two issued and four pending.

For more information, visit: www.HealthyExtractsinc.com, www.BergametNA.com or www.Fuel4Thought.com.

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is working closely with manufacturing partner Lighthouse Imaging on its proprietary i/Blue Imaging System(TM) and is on target to conduct private demonstrations at the annual American Urology Association meeting set for early September. “The updated product design will incorporate changes intended to meet critical verification requirements established through benchmark testing of competitive systems and feedback from preliminary meetings with the FDA,” reads a recent article. “The additional testing and specification development focused on the contrast agent-induced fluorescence and the ability to replicate the clinical observations in bench-level settings. The sensitivity of the system can now be demonstrated with the established testing methods. ‘We’re creating the potential for additional IP that will make the i/Blue Imaging System unique and innovative and strengthen the demand for blue light cystoscopy,’ said Jim Hutchens, Imagin’s president and CEO. ‘Patients have been hearing about the superiority of blue light over white to identify bladder cancer tumors and are searching for facilities that provide it.’”

To view the full article, visit https://ibn.fm/1DrFb

About Imagin Medical

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue(TM) Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

A team of medical device developers, neuroscientists, surgeons and engineers from the University of California San Diego is working on developing better customized maps that will be useful to physicians during brain tumor removal surgery.

Maps do already exist that physicians can reference. However, one individual’s brain isn’t the same as another’s, which is why customized maps are needed. Additionally, an individual’s brain may sometimes reorganize itself as a response to damage caused by…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

DSG Global (OTCQB: DSGT) is an emerging global technology company with interconnecting businesses in rapidly growing market segments. A recent article discusses the company’s roots in the golf industry and move into road-ready electric vehicles for delivery in the third quarter of 2021. “In 2019, the company secured exclusive North America distribution rights for Jonway Automobile Co. road-ready electric vehicles (‘EVs’). Jonway, based in Zhejiang, China, began manufacturing new vehicles s in 2003 and today produces electric powered cars, trucks, vans, SUVs, and scooters. Jonway vehicles are exported to more than 80 countries and are built to comply with U.S. safety and environmental standards,” reads the article. “These vehicles are being sold via DSG’s wholly owned subsidiary, Imperium Motor Company (‘IMC’). The move into consumer vehicles capitalizes on the company’s strength in the selection and distribution of EVs, the ability to work with large manufacturers and in application of proprietary technology unique to DSG. DSG’s advanced fleet tracking can be integrated into Jonway EVs to offer a customized scalable and integrated solution to meet the needs of small businesses and large enterprises.”

To view the full article, visit https://ibn.fm/P8WzK

About DSG Global Inc.

DSG Global is an emerging global technology company with an array of interconnecting businesses in some of the fastest growing market sectors. With roots in the golf industry, in which it specializes in fleet management with patented analytics, mobile touch screen engagement and electric golf carts under the Vantage Tag Systems (“VTS”) brand, the company is moving quickly with road-ready electric vehicles through its Imperium Motor Company subsidiary. For more information, visit www.Vantage-Tag.com and www.ImperiumMotorCompany.com.

NOTE TO INVESTORS: The latest news and updates relating to DSGT are available in the company’s newsroom at https://ibn.fm/DSGT

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

• Collaboration will use TumorGenesis’ expertise in cancer cell culture growth media in combination with Cellevate’s specialty in emerging field of nanofiber matrixes.
• Cutting-edge technology can help avoid mistakes in $2.6 billion process of bringing new drugs through FDA process.
• Coupling companies’ technology will give researchers ability to grow ovarian cancer tissues in 3D matrix support system with right media for right ovarian cancer cell types

Getting a drug through the complete FDA process, from pre-clinical to approval, is an arduous and expensive task, although there are signs that approval rates are accelerating after years of decline. Companion diagnostics, new approaches and technology are playing important roles in increasing the chances of a drug’s success from the outset—a fact not lost on stakeholders when making investment decisions (https://ibn.fm/t4SkS). Raising the success rate for experimental cancer drugs starts in the laboratory, where leading-edge technology could be instrumental in providing prescient insights that ultimately result in better clinical outcomes. Looking to give oncology drug developers an upper hand, TumorGenesis, a subsidiary of… Read More>> NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals’ (NASDAQ: CNSP) lead drug candidate, Berubicin, is a novel anthracycline, the first of which to appear capable of crossing the blood-brain barrier based on limited clinical data. The company is currently developing Berubicin in the treatment of several serious brain and central nervous system oncological indications. CNS is set to commence patient enrollment in a potentially pivotal study to evaluate the efficacy of Berubicin for adult glioblastoma multiforme (“GBM”) in the second quarter. Additionally, its sublicensee partner in Poland, WPD Pharmaceuticals, will initiate a Phase 2 multicenter clinical trial of Berubicin in adult GBM patients and is also scheduled to launch the first-ever Phase 1 pediatric trial for Berubicin during the second half of the year. A recent article quoted CNS CEO John Climaco, who underlined that 2021 is poised to be an exciting year for the company. “Throughout the first quarter, we have made continued development and regulatory progress on all fronts,” Climaco said. “We are committed to driving our novel treatments forward as expeditiously as possible with the primary focus on our Berubicin program to improve patient outcomes for GBM.”

To view the full article, visit https://ibn.fm/I0bgw

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme, an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently announced its drug formulation and development, conducted primarily by its wholly owned German subsidiary, Vektor Pharma TF GmbH, are on schedule and continue to expand in scope. A recent article reads, “A Q1 trial announced in January 2021 and focusing on a human bioavailability pilot study of the Rotigotine transdermal patch for Parkinson’s Disease was completed in March 2021. Due to the favorable outcome of the study, the Rotigotine development program will be advanced to include a pivotal human trial.” The article, which documented XPhyto’s advancements so far, highlighted the company’s pilot project in partnership with Spitzweg Apotheke, a well-known pharmacy in Langen, Germany. “Also, earlier this year, the company announced the intention to purchase a property in Biberach, Germany, where it plans to build a new commercial drug manufacturing facility.”

To view the full article, visit https://ibn.fm/H6ywr

About XPhyto Therapeutics Corp.

XPhyto Therapeutics works with the most promising disrupters in the pharmaceutical industry; accelerates research and technology development; and commercializes products with an entrepreneurial approach and a commitment to efficiency, effectiveness and accessibility. The company’s network spans Europe and North America, with companies at the forefront of diagnostics and drug formulations, and universities specializing in research on the use of psychedelics and cannabinoids. To learn more, visit the company’s website at www.Xphyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Kaival Brands (OTCQB: KAVL), the exclusive global distributor of products manufactured by Bidi Vapor LLC, has released Q2 numbers along with announcing the largest first-time order for the BIDI(R) Stick disposable electronic nicotine delivery system (“ENDS”) that the company has received. The order, one of two which the company noted in the announcement, was from Grocery Supply Warehouse Inc. (“GSW”), which services more than 25,000 stores; the order was for an estimated $22.4 million of product. The second order was from C-Store Master. The two orders together total $41.6 million and are representative of interest in the BIDI Stick product as well as the success of the company’s shift to large wholesalers and distributors versus smaller retailers. In the announcement, Kaival also reported revenue of $18.1 million for its fiscal second quarter, ended April 30, 2021. “This shift in strategy also helps us remain an industry leader in our effort to continually exceed Prevent All Cigarette Trafficking Act compliance requirements,” said Kaival Brands CEO Niraj Patel in the press release. “The BIDI Stick experience is unrivalled, as evidenced by our leading market share within the ENDS category. While the potential contract values of additional national retailers are significantly higher than those of smaller retailers and wholesalers, the process to navigate these substantial contracts is more onerous and time consuming, but one which Kaival Brands believes is worth the investment because, as mentioned above, the company is optimistic that more large orders will follow.”

To view the full press release, visit https://ibn.fm/Mcg6k

About Kaival Brands Innovations Group Inc.

Based in Grant, Florida, Kaival Brands is a company focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. The company’s vision is to develop internally, acquire, own or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. Kaival Brands is the exclusive global distributor of all products manufactured by Bidi Vapor. For more information about the company, visit www.KaivalBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Researchers from the Rogel Cancer Center at the University of Michigan have sequenced the RNA of single cells in cancerous and benign kidney tumors. Using that information, they have  determined cells from which various subtypes originate and how the tumor micro-environment affects the development of cancer and an individual’s response to treatment.

The researchers’ discoveries were reported in “Proceedings of the National Academy of Sciences” journal and will be useful in helping better understand what impacts renal cell carcinoma and in assisting…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

RYAH Group (CSE: RYAH), a connected device and big data and technology company, is working with doctors as well as government and university research centers to reduce the variations in treatment plans and trials. The company, which has developed and uses dose-measuring internet-of-things (“IoT”) devices to collect HIPPA-compliant data to improve future medical treatments, is guided by the need to transform patient care. Key to this focus is utilizing big data and AI to reshape how the world understands plant-based medicine. A recent article reads, “RYAH partners with doctors to improve the standard of care for patients and researchers to provide a complete turnkey solution for clinical trials to be compliant and standardized. Retailers and product suppliers also benefit from RYAH’s suite of dose-control products, generating recurring revenue streams and strengthening their product offerings. RYAH is working to remove any unnecessary obstacles and maintain a low entry barrier for dispensaries and smaller partners.”

To view the full article, visit https://ibn.fm/s39PA

About RYAH Group Inc.

RYAH is a connected device, and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries, pharmaceutical companies, and licensed processors (“LPs”) to monitor and manage formulation effects on patient and demographics. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation lifecycle. For more information about the company, please visit www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• Brain cancer drug developer CNS Pharmaceuticals is actively enrolling patients for a potentially pivotal Phase 2 trial of the company’s lead drug candidate, Berubicin, a promising candidate for treating a devastating condition
• CNS’s focus has been on developing a means of combating glioblastoma, a fatal, generally incurable class of brain cancers that are aggressive and recurrent amid current surgical and chemotherapy interventions
• One patient from the Phase 1 trial of Berubicin 15 years ago remains cancer-free, as assessed in November, despite glioblastoma’s reputation for proving fatal generally within about 15 months of diagnosis
• CNS recently announced it will be included in the Russell 2000 Index of small-cap companies for the coming year, effective June 25, which it expects to boost its visibility among investors

As novel biopharmaceutical CNS Pharmaceuticals (NASDAQ: CNSP) approaches its annual meeting of stockholders scheduled for June 28, the company is enthusiastically pursuing enrollment of about 243 brain cancer patients in a clinical trial designed to analyze the efficacy and safety of the company’s lead drug candidate. The Phase 2 trial will compare the drug Berubicin’s response to established chemotherapy drug lomustine in treating glioblastoma (“GBM”), a fatal class of brain cancers generally considered incurable which usually only leaves patients about 15 months to live on average once they are diagnosed. Patient enrollment began… Read More>> NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

• The company has developed and brought to market a pediatric NeuroCap
• EEG testing in pediatrics may help diagnose autism, one of the fastest-growing developmental disorders in the US, and provide better treatment for pediatric patients with epilepsy
• COVID-19 made the process challenging but the team completed their task on time despite no in-person contact and the process coming to a halt twice due to shutdowns

Brain Scientific (OTCQB: BRSF), a health care company on a mission to modernize brain diagnostics with cutting-edge technologies, has developed and brought to market a pediatric-specific disposable EEG cap. The pediatric NeuroCap may aid in diagnosing autism and providing much needed information in treating pediatric epilepsy. Autism is difficult to diagnose, yet the earlier it is discovered, the better the possibility of preventing some of the behaviors. A study published in the Scientific Reports Journal stated that EEGs can be used to accurately predict or rule out autism in children as young as three months (https://ibn.fm/t3KJq). One in fifty-nine children is… Read More>> NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company, has created powerful yet affordable solutions that bring brain diagnostics to settings where it was previously impossible or difficult to conduct neurological testing. Concussions resulting from head trauma in contact sports are usually minor; however, some can lead to significant long-term cognitive, physical and psychosocial impairments. “Unfortunately,” observes a recent article, “at this moment, it is challenging to differentiate between the two.” CT is the most commonly used imaging procedure but is not effective when conducting a post-concussion examination. MRIs and neuropsychologic testing are somewhat more effective but are time-consuming. Even so, EEG and qualitative EEG (“QEEG”) procedures are proving valuable; their value may lie in pre- and post-concussion comparisons where pre-trauma readings would be compared to post-trauma readings of the same patient. “With portable devices, sideline-based concussion assessment could help identify indicators consistent with acute TBI [traumatic brain injury] and concussion during the game. Portable EEG diagnostics is precisely the space that BRSF aims to revolutionize. With the company’s two FDA-cleared devices, NeuroCap(TM) and NeuroEEG(TM), it is now possible to conduct quick and reliable EEG testing in minutes… to diagnose concussions and other head trauma that occur on the field without transporting a patient to the hospital.”

To view the full article, visit https://ibn.fm/N6fre

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• Company’s i/Blue Imaging System(TM) is expected to be completed in 2022
• The American Cancer Society estimates that 2021 will see 83,370 new cases of bladder cancer and approximately 17,200 deaths
• More than half of the patients who underwent a cystoscopy to remove non-muscle-invasive bladder cancer will experience recurrence
• The bladder cancer market was valued at $3.43 billion in 2020, and is anticipated to reach $4.71 billion by 2028

According to the American Cancer Society, new cases of bladder cancer in the United States are expected to reach 83,730 in 2021 and deaths are anticipated to reach 17,200 (https://ibn.fm/zNRWl). Approximately 50% of patients who have had minimally invasive surgery to remove non-muscle-invasive bladder cancer will see their cancer return (https://ibn.fm/cdSKN). Scientists’ current areas of focus include the identification and causes/predictors of recurrence, as bladder cancer remains not only one of the most prevalent forms of cancer, but also one with a very high recurrence rate. To potentially help lower this high recurrence rate, surgical imaging company Imagin Medical (CSE: IME) (OTCQB: IMEXF) is finalizing the design-for-manufacturing of the i/Blue Imaging System, an innovative technology designed to significantly improve surgeons’ ability to visualize… Read More>> NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

• Company expects reporting on interim analysis for the first 18 patients of a Phase 2 multicenter clinical trial of Berubicin in adult GBM patients during the first half of 2022
• One patient from the first Berubicin trial has survived cancer-free for 14 years, while two patients saw tumor reduction of up to 80 percent
• CNS Pharmaceuticals reported a net loss of $3.6 million, attributed to increased personnel, activity preparing for clinical trials, drug manufacturing, and labor for the Phase 2 study
• The global brain tumor therapeutics market is expected to grow at a CAGR during 2020-2025, resulting in forecasted market size of $1.6 billion by 2025

CNS Pharmaceuticals (NASDAQ: CNSP), a developer of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently reported the summary of financial results for the first quarter of 2021. For the period ending March 2021, CNS reported research and development expenses in excess of $2.2 million, compared to $0.6 million for the same period in 2020 (https://ibn.fm/6GRIf). The expenses incurred are due to the drug manufacturing and labor related to the preparation for the Phase 2 study. An approximate total of $1.4 million was spent on general and administrative expenses, which is in line with the $1.3 million spent during the same period in 2020. The company reported that the three months ending March 2021 resulted in a net loss of approximately $3.6 million compared to the approximately $2.0 million for the comparable period in 2020. CNS attributes the… Read More>> NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

A recently released study discovered that individuals who routinely consumed processed meat along with sugary drinks and snacks that were high in sodium tended to have smaller left hippocampi, which is the part of the brain that is responsible for mental health, learning and memory.

The study, which was conducted by researchers from the Australian National University and Deakin University, also found that older individuals who consumed healthier diets had…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to Healthy Extracts Inc. (OTCQB: HYEX) are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

United Medical Equipment (“UME,” “UMEBSNI”) stands out in an environment fraught with fraudsters who emerged due to the soaring demand for personal protective equipment (“PPE”). “As the virus spread, an immediate and drastic need for personal protective equipment exploded. This soaring demand for PPE was quickly accompanied by PPE-related fraud,” notes a recent article. PPE fraud involves selling counterfeit testing kits, surgical gowns, gloves, facial masks, and cleaning products, as well as making false or misleading efficacy claims. “As a trusted supplier of FDA-approved COVID-19 rapid antibody test kits and PPE equipment, UME stands out in this environment where buyers can potentially fall prey to those selling counterfeit or faulty equipment. In this pandemic where adequate PPE equipment is critical for saving lives, UME is committed to differentiating itself as a premier provider of vital PPE products, delivering affordable and dependable PPE and other crucial medical supplies and durable medical equipment.”

To view the full article, visit https://ibn.fm/tM0vD

About United Medical Equipment Business Solutions Network Inc.

United Medical Equipment Business Solutions Network offers reliable resources and solutions that are designed to meet the ever-changing needs of an aging population, which includes seniors and veterans. The company’s owners and founders bring decades of combined business, military, and cardiovascular critical care nursing experience. United Medical Equipment understands the needs and concerns of the aging population, including veterans and their families, and offers the support, solutions, and reliable information critical in making informed decisions. UMEs’ mission is to provide guidance for caregivers, veterans, the aging population, and the medical community through its medication management and telehealth applications by providing reliable resources, products, and support services designed to meet unique needs. For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to UME are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed and patented its i/Blue Imaging System(TM), which will directly address the problems associated with treating early stage bladder cancer using existing cystoscope technology. “Current technology shows only one image at a time, requiring the surgeon to constantly switch back and forth between the white and blue light images. The switching process makes orientation and navigation within the bladder a challenge for surgeons,” explains a recent article. Imagin’s system will display real-time white and blue light images simultaneously, side-by-side, removing the challenge of constantly switching and reorienting. In addition, unlike current BLC technology, the i/Blue Imaging System will adapt to most endoscopes on the market. “With this major roadblock removed, Imagin believes its i/Blue Imaging System will expand the adoption of BLC and lead to more successful surgical outcomes, with the potential of and fewer recurrences of this notoriously stubborn and expensive cancer.”

To view the full article, visit https://ibn.fm/GWm01

About Imagin Medical

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

 

Galileo Life Sciences (OTC: MDRM), a company strategically focused on the telehealth and telemedicine industry, today provided an update on its progress in providing next-generation telehealth services. Innovations in telehealth have enabled health care providers with superior technology, allowing them to diagnose, treat and monitor the state of their patients with greater efficiency. However, video conferencing, the key tool in most telehealth technologies, limits the ability of physicians to check the patients’ vitals. Galileo Life Sciences, through its partnerships with various technology organizations, has established a unique platform that is connected with medical devices, which enables physicians to check patients’ vitals in real time. “I strongly believe that establishing a chain of virtual clinics as the backbone of our offering will uniquely position Galileo as a full-service telehealth company,” said Galileo’s Medical Director Gilbert Sharpe. “We are able to offer patients the option to seek treatment via a video call, attend a virtual clinic for a more thorough examination, or request a house call by one of our nurse practitioners who will bring the doctor to you via our home care devices. The clinics will be located in pharmacies or near pharmacies thus providing a patient a one-stop doctor’s visit to get the prescription filled.” To view the full press release, visit https://ibn.fm/TK0ZV About Galileo Life Sciences Inc. Galileo Life Sciences is a company strategically focused on the telehealth and telemedicine industry and is planning to offer services on a global scale. The company is dedicated to offering the most robust telehealth platform incorporating artificial intelligence (“AI”) and internet of things (“IOT”) so that anyone can get access to quality health care regardless of location and financial status. The company is committed to providing health care to those who cannot afford it. The Galileo Smart Clinics with integrated medical devices make this company unique, separate from the rest in the field. With Galileo Life Sciences, physicians can get direct access to the patient’s vitals and examine the patient in real-time without affecting the quality of care. For more information, visit www.MDRMInc.com. About BioMedWire BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that the company will be added to the Russell 2000(R) Index, effective June 25, 2021, after the close of the U.S. equity markets. CNSP will be added following the annual reconstitution of the Russell stock indexes. According to the announcement, the Russell 2000 Index, which is a subset of the Russell 3000(R) Index, measures the performance of the small-cap segment of the equity market in the United States and includes an estimated 2,000 of the smallest securities based on a combination of their market cap and current index membership. Investment managers and institutional investors commonly rely on the Russell Index for index funds and as benchmarks for active investment strategies; approximately $9 trillion in assets are benchmarked against Russell’s U.S. indexes. The indexes are part of global index leader FTSE Russell, which provides innovative benchmarking, analytics and data solutions for investors worldwide. “We are pleased to meet this noteworthy milestone and be included in the Russell 2000 Index,” said CNS Pharmaceuticals CEO John Climaco in the press release. “As our team continues to drive our clinical program forward for the treatment of glioblastoma multiforme (‘GBM’), we believe this inclusion well-positions us to drive market awareness. We are honored to be listed among our industry peers on what is considered to be a widely respected performance benchmark for small-cap companies. We look forward to leveraging the access and positioning this inclusion brings to unlock additional value.”

To view the full press release, visit https://ibn.fm/mQmxX

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer.

Additionally, the company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information about the company, please visit www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• BRSF has partnered with Ehave to conduct research connected to biochemical biomarkers concerning psychedelic drug administration
• Psychedelic drugs show promise in treating neurological disorders, including chronic pain, depression, and PTSD, but more research is needed
• BRSF’s E-Tattoo is poised to bring benefits of biomarkers to neurological and psychiatric research; allows monitoring of patient’s brain activity in a non-intrusive way

Brain Scientific (OTCQB: BRSF) has partnered with Ehave, Inc., a provider of digital therapeutics for the psychedelic and mental health sectors, to use data and AI algorithms to statistically correlate biomarkers for the identification of psychedelic drug administration as a treatment for neurological disorders such as chronic pain, depression (major and persistent), PTSD, bipolar disorder, general anxiety, ADHD and schizophrenia. Biomarkers are essential as they can help improve diagnostic accuracy and thus improve patient outcomes. There are currently 250 biochemical markers about a broad range of the body’s organic systems and how they function, but this approach still remains a challenge for psychiatric disorders. The partnership between Brain Scientific and Ehave is intended to change this (https://ibn.fm/eX4AD). Mental health disorders are affecting more and more people worldwide — it has been estimated that 51.5 million adults (20.6%) experienced mental illness in 2019 in the US alone (https://ibn.fm/6C81O). Psychedelic drugs are increasingly becoming part of mainstream psychiatry conversation. A growing body of evidence indicates that they could be effective for treating a range of mental illnesses, especially when… Read More>> NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, was featured in the Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. XPhyto Therapeutics’ CEO and Director Hugh Rogers joined the latest episode to offer an operational update and discuss the company’s achievements and future plans. XPhyto Therapeutics recently secured European approval and launched an effective 25-minute polymerase chain reaction (“PCR”) test for COVID-19 (“Covid-ID Lab”), with an initial focus on the German market and several other initiatives underway. “This is an exciting time for the company. We’ve taken this product from invention to prototype to validation to commercial approval in about ten months,” Rogers said. He explained that Covid-ID Lab sits between a rapid antigen test and a centralized automated high-throughput PCR and offers diagnostic quality, fast results and ease of administration at point of care.

To view the full press release, visit https://ibn.fm/qBfBV

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information, visit the company’s website at www.Xphyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has entered into a definitive merger agreement to acquire Piezo Motion Corp., a leading innovator of high-precision piezoelectric motion technology. According to the announcement, the merger is designed to expand the market reach of both companies along with their ability to deliver innovative technologies to high-growth markets. Both companies have built impressive teams of scientists, engineers and executives with invaluable expertise in developing and commercializing disruptive technologies, and the acquisition will result in a single company with vast machine learning background and astute ability to address demands in the market. Currently, BRSF’s neurology products create massive amounts of data health care providers can use in determining best treatments and protocols; the new company will utilize Piezo Motion’s technology to enhance these products. “We are excited for the future that the merger with Piezo Motion is expected to bring,” said Brain Scientific founder Dr. Baruch Goldstein in the press release. “Together, we plan to achieve rapid expansion while delivering and developing the new generation of MedTech solutions for the brain diagnostics market, including innovative products for long-term monitoring and brain e-tattoo. This combination offers a significant opportunity to be part of a company well positioned for growth. We look forward to uniting with Piezo Motion in what we expect will be an exciting new chapter ahead.”

To view the full press release, visit https://ibn.fm/KbPDO

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

A study carried out by a group of social and behavioral researchers from North America and Iceland has discovered that the coronavirus has had a harmful effect on adolescent mental health, particularly in girls. This study is the first to look into and record the gender and age-specific changes in adolescent substance use and mental health issues during the coronavirus pandemic, while taking into consideration the trends observed prior to the pandemic.

The researchers’ findings were reported…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

• XPhyto’s distribution, storage, and logistics partner, Max Pharma GmbH, began the sale and delivery of its rapid test kits (Covid-ID Labs) in Germany on May 25
• Max Pharma will sell Covid-ID Labs at volume-dependent pricing comparable to other COVID-19 PCR test products on the market
• The announcement comes as Germany reopens, meaning XPhyto is likely to benefit from a raft of regulatory requirements instituted by the government, which could potentially increase demand
• The Covid-ID Labs is both fast and accurate, factors that could make it the go-to product, given the inaccuracies and low sensitivity of many rapid antigen tests

As Germany reopens thanks to a drop in new COVID-19 infections, it has adopted a strategy that mandates anyone and everyone to prove they have been tested for the virus, have recently recovered from the disease, or have been fully vaccinated before entering any public space, including shops, outdoor dining areas, and, in some cases, indoor hospitality facilities (https://ibn.fm/IOo17). Earlier in March, the government made testing accessible to all at no cost, qualifying every resident to at least one free COVID-19 test per week, a policy whose implementation has continued since. As part of the… Read More>> NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics (“DTx”) market, will be joining the broad-market Russell 3000(R) Index and the small-cap Russell 2000(R) Index at the conclusion of the Russell U.S. Indexes annual reconstitution, which will be effective after the U.S. equity markets open on Monday, June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on June 4, 2021. The annual reconstitution of the Russell indexes identifies the 4,000 largest U.S. stocks as of May 7, 2021; it also ranks them by total market capitalization. Once a company joins the Russell 3000 Index, the membership lasts for one year, until the index conducts its annual reconstitution. Membership in the index also includes automatic inclusion in the large-cap Russell 1000(R) Index or small-cap Russell 2000 Index along with appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes by evaluating market-capitalization rankings and style attributes. “Inclusion in the Russell indexes reflects the hard work and achievements of the entire Dario team as we work to build the premier digital health and therapeutics company,” said DarioHealth CEO Erez Raphael in the press release. “We look forward to a heightened awareness of our company that inclusion in these widely-followed indexes confers.” To view the full press release, visit https://ibn.fm/sUii7 About DarioHealth Corp. DarioHealth Corp. is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. Dario’s next-generation, AI-powered, digital therapeutic solutions support more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software and coaching to help individuals improve health and sustain meaningful outcomes. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The company’s cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. Dario makes the right thing to do the easy thing to do. For more information about the company, please visit www.DarioHealth.com. NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO About BioMedWire BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork

• Ehave announced it will utilize BRSF’s tech in an upcoming ketamine clinical study
• BRSF’s tech will make it possible to correlate biomarkers for the identification of chronic pain, depression, PTSD, bipolar disorder, and more.
• The data from this clinical trial has the potential to provide longitudinal insights that can link brain analysis and psychedelics

Brain Scientific (OTCQB: BRSF), a commercial-stage health care company, is on a mission to modernize brain diagnostics with cutting-edge tech that bridges the widening gap in access to quality care. The company’s technology will be part of a ketamine clinical study conducted by Ehave, Inc. (OTC: EHVVF) to establish the statistical correlation between ketamine treatment and patient improvement. To read Ehave’s full announcement regarding the Ketamine Clinical Trial, go to https://ibn.fm/VMu6o. Ehave is a leading provider of digital therapeutics for the psychedelic and mental health sectors. The company’s primary goal is to improve standard care with digital therapeutics to prevent or treat… Read More>> NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

According to recently released research, patients who suffer from inflammatory bowel disease and major depressive disorder have higher healthcare burdens and discharge rates, as well as increased morbidity.

Major depressive disorder, which is sometimes referred to as clinical depression, affects an individual’s behavior and mood as well as physical functions such as sleep and appetite. This disorder is a common mental health condition in the United States, with data suggesting that more than 7% of adults in the country experience…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

• HYEX’s portfolio of wholly owned subsidiaries currently comprises BergametNA and Ultimate Brain Nutrients
• BergametNA, whose products target cardiovascular and immune health, sources its formulations from the Citrus Bergamot SuperFruit(TM)
• The bergamot fruit is richly packed with polyphenolic flavanones, which are known to decrease bad cholesterol, triglyceride, and glucose, as well as increase the good cholesterol
• BergaMet only uses the highest concentration of polyphenolic flavanones (“BPF”) as the higher the BPF, the greater the effectiveness of the supplement

Guided by the philosophy ‘Live Life Young Again’ and its commitment to superior health technology by engaging in the R&D of natural plant-based formulations, Healthy Extracts (OTCQB: HYEX), through its portfolio of wholly owned subsidiaries that currently comprises Ultimate Brain Nutrients (“UBN”) and BergametNA, develops, sells, and distributes proprietary products with proven health benefits. As UBN creates formulations that improve brain health, including memory, cognition, focus, and neuro-energy, BergametNA’s focus is primarily on the development of powerfully proven supplements, sourced from the… Read More>> NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX About Healthy Extracts Inc. “Live Life Young Again” Healthy Extracts Inc. (OCTQB: HYEX) serves as a platform for developing and acquiring complementary companies that feature science-forward, clinically proven, plant-based and proprietary products in select high-margin and high-growth categories within the multibillion-dollar nutraceuticals market – the first two multimillion-dollar examples of which have already been launched. Company subsidiaries BergametNA(TM) and Ultimate Brain Nutrients(TM) (“UBN”) are providers of nutraceutical natural heart and brain health supplements, including the only heart health supplement containing Citrus Bergamot SuperFruit(TM), the highest quality and concentration of polyphenols and flavonoids available anywhere in the world and exclusive to BergametNA in North America and backed by 17 clinical studies. UBN’s KETONOMICS(R) proprietary formulations improve brain health, including memory, cognition, focus and neuro-energy, and have multiple intellectual property license opportunities for monetizing the company’s portfolio. UBN has six unique formulation patents – two issued and four pending. For more information, visit: www.healthyextractsinc.com or www.bergametna.com. Forward-Looking Statements and Safe Harbor Notice All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate.” The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company’s Annual Report on Form 10-K filed with the SEC on April 1, 2020, and future periodic reports filed with the SEC. All of the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release. Healthy Extracts Inc. Las Vegas, Nevada www.healthyextractsinc.com [email protected] 720-463-1004 Corporate Communications: InvestorBrandNetwork (“IBN”) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office [email protected] About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Date: June 29-30, 2021
Online Livestream Event

Biopharma medical writing and communications professionals are invited are invited to attend DGE’s 2nd Medical Writing Innovation Strategies Conference for Life Sciences live streaming on June 29-30, 2021. The event will offer useful tips and guide medical professionals to learn innovative skills for filtering technical information that is effectively communicated for engagement.

These power-packed sessions will assist medical writers and communicators in elevating their skills that will, in turn, boost their career growth. With the increasing pressure on medical writing, professionals will learn how to…

Read More>>

For tickets to the event, please visit https://ibn.fm/tR7Rw

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Fibromyalgia is an acute illness that can present as cognitive dysfunction, lack of energy, intense fatigue and abnormal pain among other symptoms. Sometimes, individuals who suffer from this condition may experience flares, when their symptoms get too intense. This makes it harder for them to perform simple tasks, even struggling to make it to doctor’s appointments. However, the coronavirus pandemic and improvements in technology have made it possible for fibromyalgia patients to access telehealth appointments, which allows them to talk with their doctor remotely, either via tablet, phone or computer, while they’re home.

Patients can now schedule telehealth appointments with their nurse practitioners, doctors and other healthcare providers, which eliminates the need to spend energy and time getting ready for an appointment and commuting to a physician’s office. It should be noted that telehealth…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has developed sanitary, disposable EEG caps that are proving useful amid the ongoing pandemic. “When fighting a highly contagious disease, disposable technology is vital,” notes a recent article. This is where NeuroCap(TM) and NeuroEEG(TM), the company’s two FDA-cleared devices, can help. They offer cost-efficient, portable neurological monitoring.” The article observes that EEGs may offer a much-needed solution given that neurological conditions associated with COVID-19 are challenging to diagnose. “For example, the diagnosis of encephalopathy, one of the most frequently occurring neurological conditions in COVID-19, is mainly clinical and heavily hindered by the severe physical illnesses of hospitalized infected patients… With sanitary, disposable EEG caps, BRSF’s revolutionary solution helps health care workers get a quick, reliable picture of a patient’s condition while ensuring that the virus is not spread through the equipment. BRSF’s EEG caps, designed for single use, are also easy to place, within minutes, which helps shorten person-to-person exposure, minimizing cross-contamination risk between staff and patients.”

To view the full article, visit https://ibn.fm/tN2Ct

About Brain Scientific Inc.

Brain Scientific is a commercial-stage healthcare company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices, or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• Further refinement of if the i/Blue Imaging System will incorporate changes intended to meet critical verification requirements established through benchmark testing of competitive systems as well as feedback from preliminary meetings with the FDA
• Bladder cancer is anticipated to cause over 1,000,000 physician consultations per year, resulting in $4 billion in total costs for bladder cancer treatment and management
• Imagin Medical plans to complete its proprietary i/Blue Imaging System in 2022

The National Cancer Institute (“NCI”) lists urinary bladder cancer as the sixth most prevalent form of cancer in the United States. In 2021, NCI estimates that the total number of new bladder cancer cases will total 83,730, with deaths estimated at 17,200. The recurrence rate for bladder cancer is greater than 50%, making it one of the highest recurrence rates of all cancers. Approximately 724,000 people live in fear that their cancer will return (https://ibn.fm/BST5x). Continuous monitoring of patients who might suffer a recurrence of bladder cancer will generate over 1,000,000 physician consultations per year. These visits add to the $4 billion in costs for bladder cancer management. It is estimated that 25% more tumors are removed using blue light cystoscopy (“BLC”), a more recent technology, that works in conjunction with white light, reducing recurrence and monitoring… Read More>> NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

In the past few decades, there has been a considerable decline in the mortality rate related to bladder cancer. This, researchers speculate, may be associated with a reduction in smoking, advances in treatment and enhancements in bladder cancer diagnosis. Additionally, new therapies and more information about this disease have facilitated a change in this field, which allows health practitioners to have a better understanding of the ailment, thus saving more lives.

However, bladder cancer is still among the most common cancers in the Unites States and also the most expensive, with regard to cancer care. The majority of diagnosed bladder cancers are urothelial…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Healthy Extracts (OTCQB: HYEX), through its wholly owned subsidiary BergaMet NA(TM), has developed HERHEART(TM), an exclusive supplement scientifically formulated specifically for women to improve perimenopausal symptoms and cardiovascular health. The supplement’s development was influenced by the statistic that cardiovascular disease is the leading cause of death in women globally. A recent article notes, “A 2020 clinical study revealed that HERHEART reduced mood swings and hot flashes by 40% and 60%, respectively, increased energy by 45%, and improved arousal, comfort and desire by between 40% and 70%. It also reduced cholesterol levels, acted as an anti-inflammatory agent and metabolized fat. Dr. Nesochi Okeke-Igbokwe MD. M.S., a trusted and respected international health expert who recently joined HYEX’s Medical Advisory Board, recommends HERHEART to women. ‘This is a supplement that is terrific for women of all ages and has a whole host of health benefits.’”

To view the full article, visit https://ibn.fm/emLPn

About Healthy Extracts Inc.

“Live Life Young Again”

Healthy Extracts serves as a platform for developing and acquiring complementary companies that feature science-forward, clinically proven, plant-based, and proprietary products in select high-margin and high-growth categories within the multibillion-dollar nutraceuticals market – the first two multimillion-dollar examples of which have already been launched.

Company subsidiaries BergaMet NA(TM) and Ultimate Brain Nutrients(TM) (“UBN”) are providers of nutraceutical natural heart and brain health supplements, including the only heart health supplement containing Citrus Bergamot SuperFruit(TM), the highest quality and concentration of polyphenols and flavonoids available anywhere in the world and exclusive to BergaMet NA in North America and backed by 17 clinical studies. UBN’s KETONOMICS(R) proprietary formulations improve brain health, including memory, cognition, focus, and neuro-energy, and have multiple intellectual property license opportunities for monetizing the company’s portfolio. UBN has six unique formulation patents — two issued and four pending.

For more information, visit: www.HealthyExtractsinc.com, www.BergametNA.com, or www.Fuel4Thought.com.

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

United Medical Equipment (“UME,” “UMEBSNI”) helps families with resources and provides a network of reliable solutions such as the Medication Management App. Available on both iOS and Android, the app is designed to provide direct and indirect patient care and education for care professionals, caregivers, students, and family members. “GoodRX is the newest addition to the app’s functions,” reads a recent article. “This feature allows users to view discount prices and coupons while managing medications all within the app. In addition, GoodRX offers same-day appointments with an online health care provider, access to at-home lab tests or tests at a nearby service center, and all at minimal costs. The company also brings additional information to the platform that has been reviewed for accuracy by medical and health care experts. The Medication Management App is one more way that United Medical Equipment is providing reliable resources and solutions to fit the ever-changing needs of an aging population.”

To view the full article, visit https://ibn.fm/zIYMb

About United Medical Equipment Business Solutions Network Inc.

United Medical Equipment Business Solutions Network offers reliable resources and solutions that are designed to meet the ever-changing needs of an aging population, which includes seniors and veterans. The company’s owners and founders bring decades of combined business, military and cardiovascular critical care nursing experience. United Medical Equipment understands the needs and concerns of the aging population, including veterans and their families, and offers the support, solutions and reliable information critical in making informed decisions. UMEs’ mission is to provide guidance for caregivers, veterans, the aging population, and the medical community through its medication management and telehealth applications by providing reliable resources, products and support services designed to meet unique needs. For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to UME are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• Americans pay more for prescription drugs than any other nation in the world; prices keep increasing
• Patients pay about 14% of prescription drug costs out of pockets; around 20% report not being able to complete a prescribed course of medicine due to costs
• UME’s committed to providing consumers better access to the healthcare they need; its Medication Management App features GoodRx in-built functionality enabling them to view discount prices and coupons

United Medical Equipment Business Solutions Network (“UME”) has developed the Medication Management App with twelve different functionalities within the convenience of one application, with the newest addition of GoodRX — a feature that allows users to save money on prescription drugs. Prescription drug spending in the US eclipse that in all other countries — on average $1,200 per person per year — mainly due to high prices of brand-name drugs, which have been increasing faster than the consumer price index (https://ibn.fm/4wdP7). Market exclusivity protected by monopoly rights and patents allows manufacturers to set high drug prices. The prices usually fall after the exclusivity period ends and generic drugs become available, but access to them may be postponed by numerous business and legal tactics. Another contributing factor to… Read More>> NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

• Most extensive research to date reports significant neurological problems in patients who suffered from so-called long-haul COVID-19
• Neurological issues range from mild to more severe such as cognitive impairment, which affects around 20% of these patients
• BRSF appears poised to be part of the solution as long-haulers need monitoring so that doctors can assess if they have neurological disorders

The neurological and psychiatric aftermath of COVID-19 has been reported, but adequately assessing the effects of the disease on brain health still remains a challenge. A new preprint analysis, representing one of the most extensive studies of neuropsychiatric symptoms among COVID-19 long-haulers, reports that patients who have been sick with COVID-19 for more than three weeks experience cognitive impairment at least six months after the infection (https://ibn.fm/OSDQx). Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, is poised to provide brain monitoring capabilities to enable clinicians to study the brain wave activity of patients with neurological conditions. So-called long COVID has gained momentum over the past year as some patients reported persistent neurological and psychiatric manifestations after their initial infection. The extensive research studied nearly 19,000 adult patients across 51 studies, discussing evidence indicating a potential relationship between COVID-19 and persistent neurological problems. These problems could range from… Read More>> NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

A report that was recently released highlights that medical service leaders from various countries believe that being prepared for crises that may arise in the future and strengthening resilience should be a top priority. The senior healthcare leaders from countries such as India, Germany and the United States, were questioned about their digitization plans. Their responses were recorded through surveys.

The coronavirus pandemic has affected many industries and economies, with more nations adopting telemedicine in their healthcare sectors and using video and phone appointments to provide consultations, as opposed to in-person visits. IDC, an industry analyst firm, forecasts that in the near future, more than half of all patients…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Imagin Medical’s (CSE: IME) (OTCQB: IMEXF) i/Blue Imaging System(TM) is designed to enhance tumor visualization and resection, potentially lowering recurrence rates. With a focus on establishing a new standard of care in the visualization of cancer during minimally invasive procedures, Imagin Medical is initially targeting bladder cancer, the sixth most prevalent cancer in the U.S. and the third most common in men. Imagin’s i/Blue Imaging System aims to enhance the capabilities of cystoscopies, the conventional method used to visualize bladder cancer during surgical procedures. “Combining the effectiveness of blue light cystoscopy with proprietary technology, the i/Blue Imaging System will improve surgical technique by displaying both white and blue light images simultaneously side-by-side in real time on one monitor,” reads a recent article. “This innovation will enable the surgeon to view cancerous cells and their margins in context for more complete removal eliminate the need to switch back and forth to resect the cancer.”

To view the full article, visit https://ibn.fm/yRXRU

About Imagin Medical

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue(TM) Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), was featured in a recent episode of the Relentless Dentist podcast. The program features interviews with thought-provoking guests offering words of wisdom to help dentists gain the courage to develop the practices and lives of their dreams. Vivos Therapeutics CEO R. Kirk Huntsman joined the broadcast, hosted by certified High Performance Coach Dr. David Maloley, to discuss his professional background, his introduction to the company’s game-changing Vivos System(R), and his efforts to commercialize the platform for the treatment of sleep-disordered breathing. “Vivos has spent the last four years, literally since late 2016, building infrastructure, and the model is working,” Huntsman said. “Our Vivos-trained independent dentists have treated close to 17,000 patients with [the Vivos System]. … Mandibular advancement was never intended to be a lifelong solution to this problem. It was intended to be palliative and temporary, but neither the medical profession nor the dental profession has any good solution for sleep apnea. … With mandibular advancement and CPAP, the underlying condition gets worse over time. … That’s not true with Vivos. What the Vivos System does that’s unique is we actually rebuild the human airway. The treatment protocol repositions the jaws forward, making the dental arches wider, and they’re doing that in a stable manner.” To view the full press release, visit https://ibn.fm/KEjyD About Vivos Therapeutics Inc. Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos oral appliances have proven effective in over 17,000 patients treated worldwide by more than 1,200 trained dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information, visit www.VivosLife.com. NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS About BioMedWire BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork

A recent study published in “Neuro-Oncology” has found that brain tumor global histology distribution differs significantly, which suggests inconsistencies in data quality and registration practices.

Researchers examined data from more than 280 cancer registries that took part in the CONCORD-3 study, which was made up of more than 670,000 adults and 67,000 children with brain tumors diagnosed between 2000 and 2014. Some countries were excluded from the analysis…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, will be presenting at the upcoming Ladenburg Thalmann Healthcare Conference. The all-virtual conference is scheduled for July 13–14, 2021. Tryp chair and CEO Greg McKee, president and chief science officer Jim Gilligan and CFO Luke Hayes will participate in the presentation. The presentation will include an overview of the company, including its pipeline, strategy and business highlights. The company executives will also participate in an analyst-led fireside chat. The presentation is scheduled for Tuesday, July 13, and will begin at 3 p.m. EDT.

To view the full presentation, register at https://ibn.fm/BqpSj

To view the full press release, visit https://ibn.fm/pFVN5

About Tryp Therapeutics Inc.

Tryp Therapeutics is a pharmaceutical company focused on developing compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders. Tryp’s lead PFN drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than five million people in the United States. The company is also preparing to initiate a phase 2a clinical study for eating disorders in partnership with the Dr. Jennifer Miller at the University of Florida. For more information about the company, please visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to Tare available in the company’s newsroom at https://ibn.fm/TRYPF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• Irina Nazarova, Brain Scientific’s marketing director, interviewed for Grit Daily, one of the top news hubs for startups, discussing exciting new product developments the company is working on
• BRSF is poised to extend the universe of EEG use cases, expanding possible markets for its disruptive products

Irina Nazarova, marketing director of Brain Scientific (OTCQB: BRSF), was interviewed for Grit Daily News, the top news source on Millennial and Gen Z startups, where she presented the latest work that the company does in the space of neurology medical devices (https://ibn.fm/CeYY3). Nazarova, who has significant marketing experience as the former Editor-in-Chief at the largest entertainment magazine in Russia, discussed with Daniela Elezovic of Grit Daily, the exciting neurological advancements made possible by the work of Brain Scientific and how the company works toward expanding what is possible in neurology space. Nazarova highlights products that the company has developed in the EEG space: NeuroCap, a ready-to-use and disposable EEG headset that allows any member of medical staff to perform routine EEG testing within minutes, and NeuroEEG, portable, wireless and miniature amplifier. NeuroCap aims to disrupt the… Read More>> NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

• With demand for PPE exploding virtually overnight due to the pandemic, PPE-related fraud involving counterfeit or faulty equipment surged
• As a reliable source of everything PPE-related, UME has established itself as a go-to provider of premier equipment that can be trusted
• The company pivoted its business model when the pandemic started to seize growing market opportunity and provide reliable, high-quality PPE essentials amid the virus outbreak

United Medical Equipment Business Solutions Network (“UME”) (“UMEBSNI”), the distributor of a comprehensive line of COVID-19 products, stands out as a trusted source of reliable and authentic personal protective equipment (“PPE”) supplies. The SARS-CoV-2 virus is mainly transmitted by inhalation of respiratory droplets, but in poorly ventilated indoor settings, aerosol transmission may also happen. For this reason, gowns, gloves, eye protection and an N95 or equivalent respirator are needed, especially in the healthcare environment. Indispensable for health care professionals caring for patients with SARS-CoV-2, PPE equipment is a lifeline (https://ibn.fm/TrStJ). When used appropriately, it considerably reduces the risk of viral transmission, so it has become a fundamental component of infection prevention and control measures. But, not all PPE is created equal. As the virus spread around the country, an immediate and drastic need for personal protective equipment exploded. This soaring demand for PPE was quickly accompanied by… Read More>> NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Scientists at Case Western Reserve University have discovered a possible new approach to control epileptic seizures. Lin Mei, chair of the Department of Neurosciences at the university’s School of Medicine and lead of the study, stated that the researchers identified a new chemical reaction that may help to better manage epileptic seizures. The research, which was conducted using mice models, was reported in the “Journal of Clinical Investigation.”

Epilepsy is a neurological disorder that brings about periods of unusual behavior and seizures, loss of awareness and sensations when brain activity…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

• BRSF announced that Maine Medical Center, a teaching hospital providing health care across Portland, Maine, and northern New England, has placed an order for Pediatric NeuroCap(TM), Company’s pediatric disposable EEG headset.
• EEG testing is increasingly needed in pediatric patients, where neurological workup faces even bigger challenges than in adults.
• BRSF has developed disposable EEG caps for adults and children to meet the needs of the pediatric neuro testing market; partners with medical facilities to expand its unique technology and respond to unmet market need.

Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare technology company developing solutions in the brain diagnostics space, announced today that Maine Medical Center had placed an order for a limited supply of Pediatric NeuroCap(TM), the Company’s pediatric disposable EEG caps. As a 637-licensed-bed teaching hospital for Tufts University School of Medicine, Maine Medical Center provides health care for the people of greater Portland, the entire state of Maine, and northern New England (https://ibn.fm/3E1LM). The Pediatric NeuroCap(TM) pre-gelled EEG headset is designed to help medical staff conduct electroencephalogram (“EEG”) testing without some of the usual obstacles found in pediatric patients. Traditional EEG testing can be a cumbersome process requiring steps such as measuring and marking the… Read More>> NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the Company’s newsroom at https://ibn.fm/BRSF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Growing public attention on the traumatic brain injuries that football players suffer while playing the sport has led to various studies on the topic being conducted. Among them is a study conducted last year and approved by the institutional review board of the Soroka University Medical Center.

The study recruited 26 nonathletes, 27 athletes who played a noncontact sport and 42 amateur American football players to participate in the study. All the participants gave their informed consent to be part of the study, with the first two groups…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment Business Solutions Network Inc. are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, was the subject of a feature piece published by Med-Tech News, a publication covering medical devices and manufacturing. The article, authored by the marketing director of BRSF, Irina Nazarova, noted that the need for EEG devices within the pediatric segment often went unmet, even though children can suffer from a number of neurological disorders, some of which could lead to more devastating outcomes if left undetected. Further, EEG testing could be used for diagnosing ADHD, a growing market need. A recent article reads, “despite the apparent unmet need in patient care, the supply and availability of EEG testing to pediatric physicians are limited. That was before Brain Scientific stepped up to the challenge. The [Med-Tech] article describes how the company responded with agility to fill the gap and establish a new innovative norm for pediatric clinicians… After plenty of consultations between the company’s in-house team of specialists and the manufacturers and the medical testers to secure high-quality products, the NeuroCap for children was born — an easy-to-use disposable headset overcoming the infection risk and inconvenience burden of traditional EEG pediatric products.”

To view the full article, visit https://ibn.fm/mgHzR

About Brain Scientific Inc.

Brain Scientific is a commercial-stage healthcare company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices, or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• There is a significant need for EEG diagnostics in pediatric patients, but traditional testing is challenging due to poorly fitting adult-sized equipment, which also increases resistance to testing
• This leaves a considerable gap in neurological care for young patients
• BRSF’s Pediatric NeuroCap steps in to solve major barriers limiting EEG monitoring in pediatric care

There is a significant need for EEG diagnostics in pediatric patients, as children can suffer from neurological conditions, but traditional EEG procedure in this setting is time-consuming, cumbersome, and inconvenient. It means that the benefits of EEG testing in pediatrics could not be fully leveraged, leaving a considerable gap in neurological care for young patients. The gap that Brain Scientific (OTCQB: BRSF), a neurology medical device and software company, is poised to close. The most common neurological disorders in children include febrile seizures, which typically do not require EEG testing. However, for some other conditions, such as febrile status epilepticus, non-convulsive seizures, non-convulsive status epilepticus, and altered mental status of unknown cause, EEG testing is of critical importance. Sometimes, it is difficult to differentiate between the two groups of conditions with… Read More>> NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

• Imagin Medical Inc. has designed a system to improve the visualization of bladder cancer during minimally invasive surgery that will display, simultaneously, white and blue light images side-by-side, to help surgeons more easily identify and locate cancerous tumors for removal
• The company’s i/Blue Imaging System(TM) has the potential to make bladder cancer detection and removal more efficient and accurate, as well as reduce recurrence rates and health care costs, targeting a global bladder cancer market estimated to reach $4.71 billion by 2026
• The company’s proprietary system has entered the manufacturing stage with their partner Lighthouse Imaging, an FDA registered and ISO 13485:2016 certified manufacturer. Imagin expects to have the final design-for-manufacturing model ready to demonstrate at the American Urological Association (“AUA”) meeting in September 2021

Bladder cancer has a one of the highest recurrence rates, with approximately 50% of patients likely to relapse, making it one of the most prevalent and expensive cancers to treat. A primary contributor to this high recurrence rate is the difficulty surgeons may have in seeing and clearly locating all of the cancerous tumors and their margins. If cancerous cells are missed and not removed, the cancer can recur. Surgeons treating early-stage bladder cancer often use a cystoscope, a long tube with a camera and light at the end, inserted through the urethra to explore the bladder. Using white light illumination, the… Read More>> NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

A recent study conducted by researchers from Ohio State University has found that a higher BMI doesn’t necessarily increase an individual’s chance of developing Alzheimer’s disease. This is despite the fact that obesity in mid-life has been associated with a higher risk of Alzheimer’s.

For their research, the scientists compared data obtained from two groups of individuals who had been diagnosed with mild cognitive impairment. One group’s disease didn’t worsen while the other’s condition…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

A recent study conducted by neurologists from the School of Medicine at the University of Pittsburg has discovered that immune cells that amass in the brain following a stroke help boost neural functions, as observed in mice models. The research, which was reported in the “Immunity” journal, showed that regulatory T cells, which are specialized immune cells, help boost functional recovery following a stroke.

The researchers stated that boosting the regulatory T cell levels through the use of an antibody complex treatment enhanced cognitive and behavioral functions in mice following a stroke. This was in comparison…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals (NASDAQ: CNSP) is focused on producing a treatment that improves on the effectiveness of established chemotherapy drug lomustine in increasing overall survival rates of glioblastoma multiforme (“GBM”) patients. GBM is an illness that is nearly 100% fatal in patients just over a year after diagnosis. CNS Pharmaceuticals’ lead drug candidate, Berubicin, has been granted investigational new drug (“IND”) status after promising findings. “Berubicin is a standout anthracycline therapy because of its novel apparent ability to cross the blood-brain barrier to combat neurological tumors. The drug was the subject of a Phase I trial some 15 years ago in which 44% of patients saw their disease stabilize or improve. One patient achieved cancer-free status that has resulted in length of survival currently far beyond standard expectations, with the most recent evaluation conducted in November 2020,” reads a recent article. “CNS recently announced it is beginning to enroll patients for its planned Phase 2 trial, so the first patient is likely to be dosed in the near term. The Phase 2 trial will compare Berubicin’s response to the effectiveness of lomustine in 243 GBM patients at about 35 clinical sites in the United States and an additional 25 sites across Europe and Asia Pacific.”

To view the full article, visit https://ibn.fm/A9TBm

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme, an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, continues to create value for a growing customer base through its subsidiaries. Researchers from one such subsidiary, Helomics, recently completed key sequencing milestones for ovarian cancer to help build its AI-driven models of the disease. “We are building a strong commercial pipeline for our unique Patient-cEntric Discovery by Active Learning (PeDAL)(TM), which we launched at the beginning of 2021,” POAI CEO J. Melville Engle was quoted in a recent article. “PeDAL brings together the key Helomics assets of real-world longitudinal data on 150,000 tumor drug response profiles and our clinically validated tumor assay with Quantitative Medicine’s active machine learning technology. We believe the PeDAL platform will revolutionize early discovery and allow our pharma partners to significantly improve the chances that new drugs will translate into the clinic, saving costs and time.”

To view the full article, visit https://ibn.fm/h4EYO

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• Cardiovascular disease is the leading cause of mortality among women globally and in the US
• Using this knowledge as the motivation, Healthy Extracts, through its wholly owned subsidiary BergaMet NA, developed HERHEART(TM)
• HERHEART is derived from the bergamot fruit, richly packed with polyphenols, and is formulated specifically for women to improve heart health and perimenopausal symptoms
• Polyphenols have antioxidant and anti-inflammatory properties and are associated with improved heart health, as well as the prevention of some heart-related conditions
• Through HERHEART product, Healthy Extracts is playing a vital preventative role in the fight against cardiovascular disease among women

Cardiovascular disease is the leading cause of death in women globally – it was the cause of 39% of all deaths in 2019 (https://ibn.fm/Rrnq8). In the US, this situation is still the same, with the Center for Disease Control noting that it accounted for 21.8% of the mortality in women of all ages, races, and origins in 2017; higher than cancer (20.7%). More dishearteningly, pregnancy predisposes women to cardiovascular disease even decades after delivery, mainly because of risk factors such as… Read More>> NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX About Healthy Extracts Inc. “Live Life Young Again” Healthy Extracts Inc. (OCTQB: HYEX) serves as a platform for developing and acquiring complementary companies that feature science-forward, clinically proven, plant-based and proprietary products in select high-margin and high-growth categories within the multibillion-dollar nutraceuticals market – the first two multimillion-dollar examples of which have already been launched. Company subsidiaries BergametNA(TM) and Ultimate Brain Nutrients(TM) (“UBN”) are providers of nutraceutical natural heart and brain health supplements, including the only heart health supplement containing Citrus Bergamot SuperFruit(TM), the highest quality and concentration of polyphenols and flavonoids available anywhere in the world and exclusive to BergametNA in North America and backed by 17 clinical studies. UBN’s KETONOMICS(R) proprietary formulations improve brain health, including memory, cognition, focus and neuro-energy, and have multiple intellectual property license opportunities for monetizing the company’s portfolio. UBN has six unique formulation patents – two issued and four pending. For more information, visit: www.healthyextractsinc.com or www.bergametna.com. Forward-Looking Statements and Safe Harbor Notice All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate.” The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company’s Annual Report on Form 10-K filed with the SEC on April 1, 2020, and future periodic reports filed with the SEC. All of the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release. Healthy Extracts Inc. Las Vegas, Nevada www.healthyextractsinc.com [email protected] 720-463-1004 Corporate Communications: InvestorBrandNetwork (“IBN”) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office [email protected] About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

• Promising results have been recorded in the first pilot study of a Rotigotine skin patch for Parkinson’s patients
• Wholly owned subsidiary Vektor is reaching a major milestone in the development of Rotigotine with the potential for a pivotal human trial
• The company is planning the construction of a new lab and manufacturing space up to 32,000 square feet in Biberach, Germany
• Pilot project involving rapid COVID-19 PCR tests has been initiated in Germany, promising efficacy and accuracy of results in as little as 25 minutes
• XPhyto is currently in talks and negotiations with distribution and wholesale partners, with a potential sales launch in Europe during Q2 2021

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, recently announced its 2021 drug formulation programs are on schedule and continue to expand in scope. The company’s drug formulation and development are conducted primarily by its wholly owned German subsidiary, Vektor Pharma TF GmbH. Vektor is focused on the development of generic and hybrid-generic drug formulations for neurological conditions, with delivery platforms that… Read More>> NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Recent research conducted by researchers from the University of Utah has found that in the next 10 years, the SARS-CoV-2 virus, which is responsible for the coronavirus, may cause no more than sniffles and coughs similar to the common cold. The researchers used mathematical models to predict how the body’s immunity changes over time. Their findings were reported in the “Viruses” journal.

Fred Adler, a professor of biological sciences and mathematics at the institution, explained that the models demonstrated a possible future that is yet to be addressed fully. He added that as people collectively develop immunity over the next decade, the severity of the coronavirus would decline. The researchers’ discovery also proposes…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Healthy Extracts Inc. (OTCQB: HYEX) are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, today announced that it will collaborate with Q1 Productions as an official media sponsor for its full event lineup in 2021. IBN also announced that BioMedWire (“BMW”), a specialized communications platform for the life sciences sector and one of the 50+ brands part of the InvestorBrandNetwork, will also be joining as an official media sponsor for Q1 Productions’ upcoming events. Over the past 15 years, Q1 Productions has established a strong reputation specializing in providing high-level educational content through a myriad of conferences, forums, webinars and other services. “We are delighted to be collaborating with InvestorBrandNetwork and BioMedWire,” said Paul Northover, CEO at Q1 Productions. “IBN’s widespread syndication network and direct reach in the life sciences industry delivers incredible exposure. Moreover, their multifaceted approach, which incorporates access to millions of followers across a range of social media platforms, helps complement our existing strategy to reach larger audiences.”

To view the full press release, visit https://ibn.fm/kPNj2

About InvestorBrandNetwork

The InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through BioMedWire (“BMW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.

For more information on IBN, visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN wherever published or re-published: https://IBN.fm/Disclaimer

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

RYAH Group (CSE: RYAH) today announced that it has completed the first shipment of the RYAH Smart Dry Herb Inhalers, which includes a delivery of approximately 10,000 RYAH Cartridges and QR Codes to an international clinic undertaking one of the world’s largest and most comprehensive clinical trials in plant-based medicine. The initial shipment is designated to be used by the clinic in a pilot run in preparation for the previously announced, UK-based study on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. “We are pleased to bring RYAH’s IoT device and integrated data solutions to the United Kingdom, providing a new level of session accuracy, patient feedback consistency and data integrity to the clinical framework in plant-based medicine research,” said Gregory Wagner, CEO of RYAH Group. “We continue to evolve our product and software solutions to help clinicians and researchers unlock breakthroughs in clinical research and analytics.”

To view the full press release, visit https://ibn.fm/qg29M

About RYAH Group Inc.

RYAH is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries, pharmaceutical companies, and licensed processors (“LPs”) to monitor and manage formulation effects on patient and demographics. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation lifecycle. For more information about the company, please visit www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently received the CE-IVD approval (European certification) of its 25-minute COVID-19 RT-PCR test kits (“Covid-ID Lab”). The approval facilitated initial sale and distribution of the Covid-ID Lab in Germany and, later, other parts of Europe, the Middle East and North America. The company also recently announced delivery of 2,000 units of Covid-ID Lab to an established medical distributor in Israel. This, subject to commercial regulatory approval and subsequent potential product distribution, signaled XPhyto’s entry into the Middle East. “These units will be used for clinical evaluation based on the European CE-IVD approval, one of several international medical device certifications recognized by the Israeli government,” reads a recent article. “The evaluation, expected to be completed within 90 days, will be conducted by the Medical Device Division of the Israeli Ministry of Health (‘AMAR’). ‘We are excited by the opportunity to expand potential distribution beyond Germany,’ said CEO Hugh Rogers. ‘We are building strong partnerships around the world, and Israel is a leading nation for COVID-19 management and research.’”

To view the full article, visit https://ibn.fm/kyltV

About XPhyto Therapeutics Corp.

XPhyto Therapeutics works with the most promising disrupters in the pharmaceutical industry; accelerates research and technology development; and commercializes products with an entrepreneurial approach and a commitment to efficiency, effectiveness and accessibility. The company’s network spans Europe and North America, with companies at the forefront of diagnostics and drug formulations, and universities specializing in research on the use of psychedelics and cannabinoids. To learn more, visit the company’s website at www.Xphyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

In what many have described as groundbreaking work, a team of researchers based at University of Minnesota Twin Cities has demonstrated how the body’s immune cells can be engineered in order to navigate the physical barriers that make it hard for an individual’s immune system to fight cancerous tumors. This study has the potential to improve how millions of cancer patients are treated.

The research paper was published in the journal…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

• POAI announced that total stockholders’ equity increased by nearly $33 million to $35.5 million
• Financial report notes net proceeds of $35.6 million from private placement, direct offering, warrant exercises
• Company subsidiaries reached several milestone achievements throughout the quarter.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, reported its financial results for first quarter 2021, the period ending March 31, 2021 (https://ibn.fm/kUVwH). The company also released key business updates along with its financial numbers. “The combination of equity transactions and retirement of our outstanding debt has brought significant value to our shareholders this quarter, as total stockholders’ equity increased by… Read More>> NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Healthy Extracts (OTCQB: HYEX), through its two subsidiaries, BergaMet NA(TM) and Ultimate Brain Nutrients(TM) (“UBN”), is focused on the research, development and sale of natural plant-based formulations offering benefits for cardiovascular and neuro health. The targeting of these two high-growth categories reflects Healthy Extracts’ commitment to strengthening its position in the multibillion nutraceuticals market. “Research and clinical studies show positive results for two leading products of the company, BergaMet North America’s HERHEART(TM) and Ultimate Brain Nutrients’ Fuel4Thought(TM) Brain Booster. Clinical studies show positive results in brain activation, sports vision, cognitive function, clarity, energy, and ketone benefits (https://ibn.fm/WGKZN),” reads a recent article. “The HERHEART(TM) formulation is scientifically formulated to support a woman’s cardiovascular health as well as managing perimenopausal symptoms (https://ibn.fm/lDylc).”

To view the full article, visit https://ibn.fm/UbIsn

About Healthy Extracts Inc.

“Live Life Young Again”

Healthy Extracts serves as a platform for developing and acquiring complementary companies that feature science-forward, clinically proven, plant-based and proprietary products in select high-margin and high-growth categories within the multibillion-dollar nutraceuticals market – the first two multimillion-dollar examples of which have already been launched.

Company subsidiaries BergaMet NA and Ultimate Brain Nutrients (“UBN”) are providers of nutraceutical natural heart and brain health supplements, including the only heart health supplement containing Citrus Bergamot SuperFruit(TM), the highest quality and concentration of polyphenols and flavonoids available anywhere in the world and exclusive to BergaMet NA in North America and backed by 17 clinical studies. UBN’s KETONOMICS(R) proprietary formulations improve brain health, including memory, cognition, focus and neuro-energy, and have multiple intellectual property license opportunities for monetizing the company’s portfolio. UBN has six unique formulation patents — two issued and four pending.

For more information visit: www.HealthyExtractsinc.com, www.BergametNA.com or www.Fuel4Thought.com.

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Researchers from the University of Birmingham have designed a microscopic imaging approach that may help improve drug screening and disease modeling as well as enhance how bio-implants are developed. 3D-printing platforms are utilized in the development of bio-printed structures using a bio-ink made up of materials, biomolecules and cells, which is passed through a tiny tube. While the method is effective, cells may sometimes get damaged as they are moved through the narrow tube.

Through the use of a microscopy technique, the scientists have assessed and found information on how cell damage occurs during the 3D-printing process. The technique, which involves the use of a blade of light that is shone on the material that flows through the tiny tube, could provide a better understanding of cell movement and the flow dynamics of bio-ink. This will allow for research on complex…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals (NASDAQ: CNSP) is on track to begin a potentially pivotal Phase 2 trial during the second quarter of 2021. This trial of CNSP’s lead drug candidate, Berubicin, in the treatment of glioblastoma multiforme (“GBM”) is currently planned to include up to 243 subjects, randomized 2:1 (162 Berubicin/81 Lomustine) with an interim analysis when 50% of the subjects reach six months in the study. “As the first anthracycline to cross the blood-brain barrier, Berubicin was specifically designed to attack a variety of primary brain cancers and cancers metastatic to the brain,” reads a recent article on the novel candidate. “Dr. Waldemar Priebe, professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center, is the original developer of Berubicin. The Phase 1 trial was completed by Reata Pharmaceuticals (NASDAQ: RETA) and showed promising results, with 44% of the trial patients experiencing significant improvement in clinical benefit. One patient from this trial has survived cancer-free for the last 14 years, while two others saw a reduction in tumor size of up to 80%.”

To view the full article, visit https://ibn.fm/kH8lJ

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme, an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently expanded its board of directors with the appointment of Dr. Christina Jenkins. Dr. Jenkins holds capital markets expertise coupled with health care experience through roles that span clinical medicine, venture capital, health plans, and health care systems. Her unique skillset, multivariate perspective and extensive experience have enabled her to create growth-optimizing strategies for health care providers while improving patients’ outcomes. A recent article discussing the appointment quoted POAI CEO J. Melville Engle as saying, “We are very fortunate to have Dr. Jenkins join our board of directors. As a medical doctor she brings additional insight and perspectives to our team. She has participated and led companies to success in health services and will have an immediate impact at Predictive Oncology and will strengthen our strategic positioning in the market.”

To view the full article, visit https://ibn.fm/dYhNJ

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is looking to change how cystoscopies for bladder cancer are performed with the goal of potentially lowering recurrence rates and ultimately helping improve patients’ lives and long-term outlook. “The company’s i/Blue Imaging System(TM) is a breakthrough cancer visualization technology currently in the manufacturing stage with Lighthouse Imaging, an FDA registered and ISO 13485:2016 certified contract manufacturer located in Maine. The project is on track for completion in 2022,” reads a recent article on the innovative solution. “Imagin Medical’s i/Blue Imaging System has the potential to revolutionize current cystoscopies by showing both white light and blue light images simultaneously side-by-side on the screen in real time, providing clear visualization of the fluoresced flat cancer cells and margins in context within the bladder. This capability eliminates surgeons’ need to change between images and can potentially lead to lower recurrence rates and help assure a better standard of care and future for bladder cancer patients. In addition, the i/Blue System will come at an overall lower system cost and, because it will adapt to most endoscopes on the market, will allow hospitals and doctor’s offices to make use of scopes they already own, adding to the savings.”

To view the full article, visit https://ibn.fm/RHuH7

About Imagin Medical

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Vivos Therapeutics (NASDAQ: VVOS) founder and chief medical officer, Dr. G. Dave Singh, DMD, PhD, DDSc, has written a new book with the intent of assisting doctors and dentists in better understanding how to address underlying craniofacial conditions that impact a patient’s overall airway, breathing and sleep health. Titled “Pneumopedics and Craniofacial Epigenetics,” the book covers craniofacial growth and developmental genetics, and addresses the connection between dentofacial anomalies and developmental deficiencies closely associated with downstream conditions such as obstructive sleep apnea (“OSA”). In addition, the book, which is available on Amazon, solidifies the scientific and biological foundation upon which VVOS’s proprietary approach is built. Vivos is focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including OSA. The company’s novel approach involves the skills of dentists who have been specially trained and the first nonsurgical, noninvasive and cost-effective treatment for people with mild-to-moderate OSA. “In many respects, this book is the culmination of my life’s work and research, starting with the theoretical foundation set forth in the Spatial Matrix Hypothesis that I first published in 2004 and continuing through the ensuing years with numerous confirmational patient studies in clinical settings,” said Vivos founder and chief medical officer Dr. G. Dave Singh in the press release. “Having the opportunity to bring this technology to the world to help patients who are suffering continues to be my mission, and the overarching goal with this book is to spread the word far and wide about how this technology can truly make a difference in how we approach thinking about and treating downstream health conditions like OSA moving forward.”

To view the full press release, visit https://ibn.fm/LE77P

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for people with mild-to-moderate OSA. or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in treating more than 17,000 patients worldwide by more than 1,200 dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology for Home Sleep Testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using the Vivos System. For more information about this company, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, is beginning its PALISADE-1 phase 3 trial. The randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of VTGN’s PH94B (“PH94B”) for the treatment of anxiety in adults with Social Anxiety Disorder (“SAD”). In the announcement, the company noted there is no FDA-approved acute treatment for the disorder. The company plans to include some 200 randomized subjects in the study, which will be held at an estimated 18 sites across the country with Dr. Michael Liebowitz as principal investigator. Liebowitz is a Columbia University psychiatrist and is the former director and founder of the Anxiety Disorders Clinic at the New York State Psychiatric Institute; he currently serves as director of the Medical Research Network in New York City and creator of the Liebowitz Social Anxiety Scale (“LSAS”). VistaGen anticipates topline results from the trial to be available mid-year in 2022. VGTN’s proprietary PH94B is an odorless, rapid-onset, investigational pherine nasal spray. “Initiation of PALISADE-1 is a major milestone for our PALISADE Phase 3 clinical program for PH94B, a program aimed at supporting a potential New Drug Application to the FDA,” said VistaGen CEO Shawn Singh in the press release. “The trial is an essential next step in our efforts to confirm the positive efficacy and safety results we have seen in all PH94B Phase 2 trials to date. PH94B has the potential to be a life-changing acute, as-needed treatment of anxiety for adults with SAD, similar to how a rescue inhaler is used to prevent an asthma attack. At a time of continuing increase in the number of Americans suffering from SAD and other anxiety disorders, and a current treatment paradigm that falls short of delivering necessary relief, a new fast-acting treatment alternative is imperative.”

To view the full press release, visit https://ibn.fm/3aXez

About VistaGen Therapeutics Inc.VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s drug candidates has a differentiated potential mechanism of action, has been well tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information about the company, please visit www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Some of the most commonly used medications, such as antibiotics, are usually administered in low doses, despite the greater therapeutic benefit they possess, because of the risk of arrhythmias. Arrhythmias occur when an individual’s heartbeat becomes irregular, beating either too slow or too fast. Cardiac arrhythmias usually occur when electrical impulses in an individual’s heart aren’t working properly.

A team of researchers from various institutions have discovered a compound that hinders cardiac arrhythmias from occurring when these drugs are given in higher doses, through experimental and computational…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Rutgers Robert Wood Johnson Medical School researchers have discovered that the coronavirus may cause blood clots in an individual’s arms. Their findings, which were reported in the “Viruses” journal, delve into how inflammation brought about by the coronavirus can result in upper extremity blood clots.

This case study is part of a bigger study by the institution involving a group of patients that had contracted the coronavirus infection and were either discharged or admitted…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment Business Solutions Network Inc. are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

RYAH Group’s (CSE: RYAH) wholly owned subsidiary, RYAH Medtech Inc., has completed initial shipment of its proprietary Smart Dose-Measuring inhalers for use in a pilot study conducted by CLINN medical center in Milan, Italy. Per the update, CLINN, the first and only cannabis-specialized clinic in Italy, named the best cannabis clinic in Europe by CanEx, is launching an observation study using RYAH devices in order to collect accurate patient feedback on consumption of cannabis strains available on the Italian market. Italy, with 30% growth over the last year, remains the second-largest market in Europe with more than 20,000 patients, which makes it a priority market for RYAH Group. “We are delighted to bring RYAH Medtech’s Smart Inhaler to the CLINN network and support CLINN in integrating their data collection software,” said RYAH’s European Business Development Manager Andrea Ferrari. “The combination of dose-control and data analytics with CLINN’s extensive acumen in plant-based medicine research will set a new standard in cannabis therapies in Italy.”

To view the full press release, visit https://ibn.fm/WaypU

RYAH Group Inc.

RYAH is a big data and technology company focused on valuable predictive analysis in the global medical intake industry. The company manages a complete digital ecosystem leveraging both internet of things (“IoT”) and artificial intelligence (“AI”) to create a dynamic data service for the medical plant industry. It is developing a suite of IoT devices, including a dry-herb vaporizer device capable of storing all plant lab results, measuring patient inhalation sessions in real-time and capturing instant feedback for plant dose management. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant medical data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is also relevant for pharmacies, clinics, growers, dispensaries, and licensed processors (“LPs”) to monitor and manage plant strain effects on patients. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete medical plant lifecycle, from seed to consumption. For more information about the company, please visit www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• Biopharmaceutical developer CNS Pharmaceuticals is working on ways to improve overall survivability for glioblastoma multiforme (“GBM”) brain cancer patients
• GBM is considered to be an incurable brain cancer that usually only leaves patients about 15 months to live once they are diagnosed, prompting research efforts to improve patients’ responses to therapeutic approaches
• A recent study found that the GBM patients most likely to succumb within a relatively short period could be identified with non-invasive MRI scans, allowing researchers to grant them priority in clinical trials
• Another recent study found patient responses could be improved simply by changing the time of day that therapy is administered to the morning
• CNS Pharmaceuticals’ lead drug candidate, Berubicin, showed promise in a small Phase 1 trial 15 years ago and now is being prepped for a larger Phase 2 trial
• Two other clinical trials are in development by sublicensee partner WPD Pharmaceuticals in Europe, including one for pediatric patients with malignant gliomas

Researchers’ recent successful efforts to identify a select set of brain cancer patients least likely to prolong survival when receiving standard treatment have been welcomed by the medical community amid efforts to develop better treatments and potential cures. The announcement by the Cimino lab at The University of Washington and Seattle’s Fred Hutchinson Cancer Research Center last month states a machine learning model has been developed that is “capable of identifying glioblastoma (‘GBM’) patients predisposed to poor survival from… Read More>> NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

• Sports concussions on the rise; with more children playing sports, it is becoming an important public health problem
• Quantitative EEG shows promise in identifying athletes with post-concussion impairments; for this, reusable EEG caps and mobile-based applications are helpful
• BRSF provides portable EEG devices that bring brain diagnostics to settings where it was previously impossible including off-site testing within sports

A recent article published by Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company operating in the brain diagnostics space, discusses how concussions or Traumatic brain injuries (“TBI”) are a significant risk for young athletes, quickly becoming an important public health issue as more and more children and teens are playing contact sports (https://ibn.fm/Jm5rT). TBI is a primary cause of death and lifelong disability in children and young adults in the United States. Centers for Disease Control and Prevention estimates that each year 1.5 million Americans sustain a TBI, leading to 50,000 deaths — one-third of all injury-related deaths — and causing long-term disability in up to 90,000 people (https://ibn.fm/F4VUm). Concussions result from head trauma in contact sports. Although they are usually minor and self-limiting, some can lead to significant long-term cognitive, physical, and psychosocial impairment. Unfortunately, at this moment, it is challenging to differentiate between… Read More>> NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

United Medical Equipment (“UME,” “UMEBSNI”) is playing a vital role in making it possible for businesses and health care facilities to maintain safety and health among employees and customers by supplying personal protective equipment (“PPE”) and rapid antibody test kits. UME’s contribution is essential now more than ever due to factors such as the uncertainty surrounding the ability of the vaccines to suppress the spread of COVID-19 completely, given the limited observation period, as well as the fact that those vaccinated can spread the virus. “By offering COVID-19 rapid kit testing, the company is doing its part and continually evolving its efforts to protect the community from COVID-19,” reads a recent article. Further, “the company works with its customers’ specific needs and goals to build a customized and flexible testing solution that works for the employer, the employees and the customer’s budget.”

To view the full article, visit https://ibn.fm/rUKLE

About United Medical Equipment Business Solutions Network Inc.

United Medical Equipment Business Solutions Network offers reliable resources and solutions that are designed to meet the ever-changing needs of an aging population, which includes seniors and veterans. The company’s owners and founders bring decades of combined business, military and cardiovascular critical care nursing experience. United Medical Equipment understands the needs and concerns of the aging population, including veterans and their families, and offers the support, solutions and reliable information critical in making informed decisions. UMEs’ mission is to provide guidance for caregivers, veterans, the aging population and medical community through its medication management and telehealth applications by providing reliable resources, products and support services designed to meet unique needs. For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to UME are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Researchers from the Institute for Health Metrics and Evaluation (“IHME”) at the University of Washington have discovered evidence suggesting that the number of individuals who have succumbed to the coronavirus is higher than official reports have indicated. The team performed an analysis on fatalities caused by the coronavirus and reported its findings on the IHME website.

Many physicians involved in the fight against the pandemic agree that the number of individuals who have succumbed to this fatal disease is higher than official reports have shown. The discrepancy in numbers is mainly because many individuals who died weren’t listed as coronavirus…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, today announced that Maine Medical Center has placed an order for a limited supply of the company’s pediatric NeuroCap(TM) disposable EEG caps for use with its pediatric patients. Maine Medical Center, with a staff of over 6,000, is a 637-licensed-bed teaching hospital for Tufts University School of Medicine. “We are happy to provide our pediatric EEG products to Maine Medical Center. The NeuroCap for children is designed to address the need for comfort, speed and reliability within the pediatric population,” said Amy Griffith, VP Strategy and Business Development for Brain Scientific. “We hope that Maine Medical Center and other hospitals see the benefits of using the product on an ongoing basis.”

To view the full press release, visit https://ibn.fm/GT3d2

About Brain Scientific

Brain Scientific is a commercial-stage health care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Healthy Extracts (OTCQB: HYEX) recently announced the addition of Dr. Joel Kahn, MD, to its medical board. Dr. Kahn, a world-renowned, triple board-certified cardiology specialist with 30 years of experience, has used BergametNA Citrus Bergamot SuperFruit(TM) on thousands of patients and approves the product’s cardiovascular health benefits. He has also personally conducted clinical studies that confirm the effectiveness of the superfruit, the main ingredient in BergametNA’s product line. HYEX CEO Duke Pitts noted that the company was delighted to welcome Dr. Kahn to its medical board. A recent article discussing this indicates that Pitts considers the addition of Dr. Kahn to the company’s already talented team of specialized doctors as instrumental in expanding doctor-to-doctor and consumer sales.

To view the full article, visit https://ibn.fm/zbORz

About Healthy Extracts Inc.

“Live Life Young Again”

Healthy Extracts serves as a platform for developing and acquiring complementary companies that feature science-forward, clinically proven, plant-based and proprietary products in select high-margin and high-growth categories within the multibillion-dollar nutraceuticals market – the first two multimillion-dollar examples of which have already been launched.

Company subsidiaries BergametNA(TM) and Ultimate Brain Nutrients(TM) (“UBN”) are providers of nutraceutical natural heart and brain health supplements, including the only heart health supplement containing Citrus Bergamot SuperFruit(TM), the highest quality and concentration of polyphenols and flavonoids available anywhere in the world and exclusive to BergametNA in North America and backed by 17 clinical studies. UBN’s KETONOMICS(R) proprietary formulations improve brain health, including memory, cognition, focus and neuro-energy, and have multiple intellectual property license opportunities for monetizing the company’s portfolio. UBN has six unique formulation patents — two issued and four pending.

For more information, visit: www.HealthyExtractsinc.com, www.BergametNA.com or www.Fuel4Thought.com.  

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

 

Recent research that was presented at the 70th Annual Scientific Session, which is held by the American College of Cardiology, has found that middle-aged and young adults who have been diagnosed with conditions such as anxiety or depression after they’ve suffered cardiac arrest have twice a higher chance of suffering from a second heart attack when compared with individuals who experience mild levels of distress.

Researchers noted that the study evaluates how mental health impacts the outlook for cardiac arrest survivors. They added that they also tracked inflammatory markers that may contribute to an increased risk of cardiovascular diseases among individuals who experience distress. The study’s findings align with results from prior studies conducted on older individuals, which supports evidence that mental….

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

• Consequences of novel Coronavirus infection on brain health are significant, requiring frequent brain monitoring
• Brain diagnostics in infected patients extremely limited due to their severe physical illnesses; traditional EEG time consuming, exposes frontline workers to virus transmission risk
• BRSF’s sanitary disposable NeuroCap(TM) helps health care workers get quick, reliable insights into patient’s condition while minimizing cross-contamination risk

Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company providing next-gen solutions to the neurology market, is poised to offer a response to brain diagnostic challenges in the hospitals’ red zones amid the pandemic. As the Company describes in one of the recent articles published on the website, the consequences of the COVID-19 pandemic on brain health are significant (https://ibn.fm/fhYxm).

While respiratory damage of novel Coronavirus is well reported, debilitating and even deadly neurological conditions may be affecting far more people infected with the virus. As the pandemic unravels and we learn more about the COVID-19, it is becoming clear that, although COVID-19 does not appear to directly attack nerve tissue, it is neurologically damaging. It is known to cause neurological injury in 1 out of 7 patients hospitalized with the infection (https://ibn.fm/aTUhK). The list of neurological diseases associated with COVID-19 infection is long and includes encephalopathy, Guillain-Barré syndrome, hemorrhagic stroke, ischemic stroke, meningoencephalitis, paralysis, and seizures. A growing body of evidence suggests that COVID-19 can have serious and potentially long-lasting effects on the brain — as many as 1 in 3 COVID-19 survivors experience neurological or a mental health disorder within six months of the infection (https://ibn.fm/Bop48).

COVID-19 appears to cause neurological injury through three mechanisms, including hypoxemia — the state of very low blood oxygen levels causing encephalopathy and neurological damage; immune dysfunction causing “cytokine storm” and blood clots.

Neurological conditions associated with COVID-19 are challenging to diagnose. For example, the diagnosis of encephalopathy, one of the most frequently occurring neurological conditions in COVID-19, is mainly clinical and heavily hindered by the severe physical illnesses of hospitalized infected patients. Investigative procedures such as MRI, lumbar puncture and cerebrospinal fluid analysis are complicated to perform on ICU patients that are on supportive care measures such as mechanical ventilation and supplemental oxygenation.

The quest for a diagnostic procedure that may offer a response in this extremely difficult and limiting setting is still ongoing – but EEG may be able to offer a solution.

EEG could be a potentially helpful study to conduct on patients with suspected COVID-19 encephalopathy. Bedside EEG testing may reveal occult, subclinical seizure activity that would otherwise go unveiled. Still, traditional EEG testing is a time-consuming task that requires placing electrodes and measuring the patient’s head, which all prolongs exposure of frontline health workers to the deadly virus.

When fighting a highly contagious disease, disposable technology is vital. This is where NeuroCap(TM) and NeuroEEG(TM), the Company’s two FDA-cleared devices, can help. They offer cost-efficient, portable neurological monitoring. With sanitary, disposable EEG caps, BRSF’s revolutionary solution helps health care workers get a quick, reliable picture of a patient’s condition while ensuring that the virus is not spread through equipment. BRSF’s EEG caps designed for single use are also easy to place – within minutes – which helps shorten person-to-person exposure, minimizing cross-contamination risk between staff and patients.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

A University of Massachusetts team has created a nanoparticle that could potentially transform the way different diseases, including cancer, are treated. The approach combines two methods that allow medicine to be delivered to targeted cells more effectively.

At the moment, one of the best new ways to deliver anti-cancer medicine is by using biologics (i.e., protein-based medications). The major benefits of this method are that the biologics have the capacity to replace proteins that have malfunctioned…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs. “Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (‘PFN’(TM)) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas,” reads a recent article regarding Tryp’s positioning. The piece also discusses the company’s three strategic initiatives. “Develop” is its first initiative, under which Tryp intends to utilize FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs. Tryp plans to protect the commercial lifespan of its drug candidates through regulatory exclusivity, patents, trade secrets and proprietary know-how. Finally, Tryp intends to seek out licensing, acquisition and co-development opportunities to monetize its drug candidates following their Phase 2 stages of development.

To view the full article, visit https://ibn.fm/fnAZE

About Tryp Therapeutics Inc.

Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and safety profiles for the treatment of rare and other diseases with unmet medical needs. Tryp’s psilocybin-for-neuropsychiatric disorders (“PFN”) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders. Tryp’s lead PFN drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than five million people in the United States. In addition to its PFN program, Tryp is developing TRP-1001, an oral formulation of razoxane for the treatment of soft-tissue sarcoma. Soft-tissue sarcomas are a rare and diverse group of tumors that account for about 1% of all cancers in adults and 7% in children. Based on the prevalence of soft-tissue sarcomas in the United States, Tryp believes it is a rare disease and that TRP-1001 should qualify for orphan drug status. For more information about the company, please visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that it will present at two investor conferences slated to take place in June. These include scheduled presentations, as detailed in the update, at the Jefferies Virtual Healthcare Conference and the William Blair 41st Annual Virtual Growth Stock Conference. Interested parties should visit the sponsor’s conference website for more information regarding these events.

To view the full press release, visit https://ibn.fm/lYl1b

About VistaGen Therapeutics Inc.

VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that Marx Pharma GmbH, the company’s distribution, storage and logistics partner, is launching Covid-ID Lab, XPhyto’s 25-minute SARS-CoV-2 (COVID-19) RT-PCR test system in Germany; the product will launch on May 25. The announcement noted that the proprietary Covid-ID Lab will be priced within the range of commonly available COVID-19 PCR test products already on the market and that initial manufacturing capacity has been determined; additional manufacturing capacity is also available if needed. XPhyto’s Covid-ID Lab requires only a 20-minute PCR run time with no prior RNA extraction; results are available within five minutes. The combines the speed of an antigen test with the accuracy of a PCR test. “Covid-ID Lab provides diagnostic level accuracy in minutes at the point-of-care. It is a specialized product that is designed to fill the market gap between disposable antigen tests and centralized automated PCR systems,” said XPhyto COO and director Wolfgang Probst in the press release. “Examples of target customers are airports, cruise lines, pharmacies, medical clinics, and any industrial or education site that requires rapid, definitive results.”

To view the full press release, visit https://ibn.fm/i8AMa

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• Seizures have been common in hospitalized COVID-19 patients, and the death rate higher in those who experienced the seizures
• Due to a shortage of PPE and limited contact, EEG accessibility was limited during the pandemic
• The  NeuroCap can fill the gap in EEG accessibility during the pandemic and into the future, as more long-term studies are created

Brain Scientific (OTCQB: BRSF) is developing innovative and proprietary medical devices and software to bridge the widening gap in access to quality care. The Company’s first commercialized devices, the NeuroCap(TM) and NeuroEEG(TM), offer cost-effective and disposable substitutes to their traditional counterparts.

The NeuroCap is FDA-cleared, minimizes cross-contamination, and can be administered by clinical staff of any level. With over one-third of coronavirus patients reporting neurological symptoms, more patients must receive EEGs that allow for limited contact and ease of use. The NeuroCap takes less than…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, was recently featured in Neoscope (a publication by Futurism) as a company that champions cutting-edge research that is shaping the future in the field of brain diagnostics. “The article details Brain Scientific’s e-tattoo technology — a series of tiny electrodes stitched beneath the skin that can get a clear reading of neural signals in real-time,” reads a recent update regarding the company and its ground-breaking technology. “The feature reports that Brain Scientific is exploring possibilities to use big data collected through e-tattoo to study the neurological precursor of epileptic seizures in patients. Whether there exists a typical pattern of brain waves before seizures occur would be invaluable information for doctors and patients alike. Still, the question remains unresolved so far. The article cites that Brain Scientific’s e-tattoo, however, could be a game-changer. E-tattoo would give researchers access to the wealth of real-time neurological data collected over a long time, something not possible to recreate in a lab.”

To view the full article, visit https://ibn.fm/QhHlR

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

New research done by a team from the University of Florida has uncovered evidence that links the manifestation of neurodegenerative diseases such as Parkinson’s, Alzheimer’s and ALS to the presence of specific bacteria types in the gut.

Previous research had pointed to gut microbiota changes in people who suffered from neurodegenerative conditions. However, the huge diversity of bacteria in the digestive tract made it a daunting task to pinpoint the specific bacteria types connected to neurodegenerative diseases. This is the challenge…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Healthy Extracts Inc. (OTCQB: HYEX) are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.